

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Annals of the ICRP

ICRP PUBLICATION 1XX

The ICRP Computational Framework for Internal Dose Assessment for Reference Workers: Specific Absorbed Fractions

Editor
C.H. CLEMENT

Associate Editor
N. HAMADA

Authors on behalf of ICRP
W.E. Bolch, M. Zankl, K.F. Eckerman, T. Fell, A. Endo, J. Hunt,
D. Jokisch, K.P. Kim, and N. Petoussi-Henss

PUBLISHED FOR

The International Commission on Radiological Protection

by

[SAGE logo]

Please cite this issue as ‘ICRP, 201Y. The ICRP Computational Framework for
Internal Dose Assessment for Reference Workers: Specific Absorbed
Fractions. ICRP Publication 1XX, Ann. ICRP 4X (0).’

34		
35		
36	ABSTRACT	3
37	PREFACE.....	5
38	MAIN POINTS.....	7
39	GLOSSARY	8
40	1. Introduction	15
41	2. ICRP SCHEMA FOR INTERNAL DOSE ASSESSMENT	16
42	2.1. Computational solutions to the ICRP reference biokinetic models	17
43	2.2. Computation of ICRP reference dose coefficients for equivalent dose	18
44	2.3. Computation of ICRP reference dose coefficients for effective dose	20
45	2.4. Implementation of specific absorbed fractions within the ICRP system	20
46	2.5. Derivation of specific absorbed fractions for distributed source organs.....	21
47	3. Computational Methods for whole body organs	22
48	3.1. The ICRP / ICRU reference computational phantoms.....	22
49	3.2. Radiation transport codes used for absorbed fraction calculations	24
50	3.3. Sampling algorithms for distributed organs and tissues.....	31
51	4. computational methods for the skeletal tissues	39
52	4.1. Models for electron transport	39
53	4.2. Models for recoil proton transport following neutron interactions	40
54	4.3. Models for alpha particle transport	41
55	4.4. Response functions for photon and neutron dose to the skeletal tissues.....	42
56	5. computational methods for the respiratory tract.....	43
57	6. computational methods for the alimentary tract.....	44
58	REFERENCES	45
59	ANNEX A	51
60	ANNEX B.....	55
61		

62 THE ICRP COMPUTATIONAL FRAMEWORK
63 FOR INTERNAL DOSE ASSESSMENT FOR
64 REFERENCE WORKERS: SPECIFIC
65 ABSORBED FRACTIONS

66
67
68
69

ICRP Publication 1XX

Approved by the Commission in Month Year

70

71 **Abstract**—Dose coefficients for assessment of internal exposures to radionuclides are
72 radiological protection quantities giving either the organ equivalent dose or effective
73 dose per intake of radionuclide following ingestion or inhalation. In the
74 Commission’s Occupational Intakes of Radionuclides (OIR) series of documents,
75 new biokinetic models for distribution of internalised radionuclides in the human
76 body are presented as needed for establishing time-integrated activity within organs
77 of deposition (source organs). These series of reports replace *Publications 30* and *68*.
78 In addition, other fundamental data needed for computation of the dose coefficients
79 are radionuclide decay data (energies and yields of emitted radiations), which are
80 given in *Publication 107*, and values of specific absorbed fraction (SAF) – defined as
81 the fraction of the particle energy emitted in a source tissue region that is deposited in
82 a target tissue region per mass of target tissue (units of kg^{-1}). This report provides the
83 technical basis for SAFs relevant to internalised radionuclide activity in the organs of
84 the reference adult male and reference adult female as defined in *Publications 89* and
85 *110*. SAFs are given for uniform distributions of monoenergetic photons, electrons,
86 alpha particles, and fission-spectrum neutrons over a range of relevant energies.
87 Electron SAFs include both their collision and radiative components of energy
88 deposition. SAF data are matched to source and target organs of the biokinetic models
89 of the OIR publication series, as well as the *Publication 100* alimentary tract model
90 and the *Publication 66* respiratory tract model, the latter as revised within *Publication*
91 *130* – OIR Part 1. The document further outlines the computational methodology and
92 nomenclature for assessment of internal dose in a manner consistent with that used
93 for nuclear medicine applications. Numerical data for particle specific and energy
94 dependent SAFs are given in electronic format for numerical coupling to the
95 respiratory tract, alimentary tract, and systemic biokinetic models of the OIR
96 publication series.

97 © 201X ICRP. Published by SAGE.

98

99 *Keywords:* Computational phantom, Absorbed fraction, Specific absorbed fraction,
100 Radiation transport, Internal dosimetry

101

102

AUTHORS ON BEHALF OF ICRP

103
104
105

W.E. Bolch, M. Zankl, K.F. Eckerman, T. Fell, A. Endo, J. Hunt,
D. Jokisch, K.P. Kim, and N. Petoussi-Henss

106

107

PREFACE

108 The membership of the Task Group on Dose Calculations (DOCAL) at the time of the
109 completion of this report was:

110

111 *Members:*

112	W.E. Bolch (Chair)	T.P. Fell	D. Nosske
113	V. Berkovski	N.E. Hertel	N. Petoussi-Henss
114	L. Bertelli	J.G.S. Hunt	M. Pelliccioni
115	A. Endo	N. Ishigure	M. Zankl
116	K.F. Eckerman		

117

118 *Corresponding Members:*

119	A. Birchall	C. Lee	R. Tanner
120	G. Gualdrini	H. Schlattl	X.G. Xu
121	D. Jokisch	M. Stabin	

122

123 The membership of the Task Group on Internal Dosimetry (INDOS) at the time of the
124 completion of this report was:

125

126 *Members:*

127	F. Paquet (Chair)	H. Doerfel	J.D. Harrison
128	E. Ansoborlo	G. Etherington	R.W. Leggett
129	M.R. Bailey	A. Giussani	J. Lipsztein
130	E.J.A. Blanchardon	R.A. Guilmette	D. Melo

131

132 *Corresponding Members:*

133	A. Bouville	C. Hurtgen	D. Nosske
134	C-M. Castellani	A. Luciani	D.M. Taylor
135	R. Cruz-Suarez	D. Newton	D. Whillans

136

137 The membership of Committee 2 during the period of preparation of this report was:

138

139 *(2009-2013)*

140	H-G. Menzel (Chair)	R. Cox	R. Leggett
141	M.R. Bailey	G. Dietze	J.L. Lipsztein
142	M. Balonov	K.F. Eckerman	J. Ma
143	D. Bartlett	A. Endo	F. Paquet
144	V. Berkovski	J.D. Harrison	N. Petoussi-Henss
145	W.E. Bolch	N. Ishigure	A.S. Pradhan

146

147 *(2013-2017)*

148	J.D. Harrison (Chair)	M. Degteva	D. Noßke
149	M.R. Bailey	A. Endo	F. Paquet
150	V. Berkovski	J.G. Hunt	N. Petoussi-Henss



151
152
153
154

L. Bertelli
W.E. Bolch
D. Chambers

C. Hyeong Kim
R. Leggett
J. Ma

F. Wissmann

155

MAIN POINTS

- 156 • Dose coefficients for assessment of internal exposure to radionuclides
157 following inhalation and ingestion require the use of biokinetic models
158 (*Publication 130*), radionuclide decay scheme data (*Publication 107*), and
159 values of specific absorbed fraction in a computational phantom.
- 160 • Specific absorbed fractions are defined as the fraction of particle energy
161 emitted in a source tissue region that is deposited in a target tissue region
162 per mass of target tissue, and are expressed in units of kg^{-1} .
- 163 • This report presents reference values of the specific absorbed fraction
164 (SAF) for internally emitted photons, electrons, and alpha particles, as
165 well as fission-spectrum neutrons associated with radionuclides that
166 decay by spontaneous fission.
- 167 • The majority of SAF values given in this report are derived from Monte
168 Carlo radiation transport simulations in the ICRP Reference Adult Male
169 and Reference Adult Female computational phantoms defined in
170 *Publication 110*.
- 171 • Additional values of electron and alpha particle SAFs are taken from
172 *Publication 66* for the Human Respiratory Tract Model, with changes
173 consistent with revisions to the HRTM presented in *Publication 130*.
- 174 • In this report, new values of electron and alpha particle SAFs are given
175 for the Human Alimentary Tract Model that supercede those given in
176 *Publication 100*.
- 177 • The reference SAFs presented in this report are numerically coupled to
178 the compartmental models of the HRTM, HATM, and the systemic
179 biokinetic models of *Publication 130* in the calculation of reference dose
180 coefficients for both organ equivalent dose and effective dose.
181

182 **GLOSSARY**

183 Absorbed dose, D

184 The absorbed dose is given by

185
$$D = \frac{d\bar{\varepsilon}}{dm}$$

186 where $d\bar{\varepsilon}$ is the mean energy imparted by ionising radiation to matter of mass
 187 dm . The SI unit of absorbed dose is joule per kilogramme (J kg^{-1}), and its
 188 special name is gray (Gy).

189 Absorbed fraction (AF), $\phi(r_T \leftarrow r_S, E_{R,i})$

190 Fraction of energy $E_{R,i}$ of the i^{th} radiation of type R emitted within the source
 191 region r_S that is absorbed in the target region r_T . These target regions may be
 192 tissues (e.g. liver) or they may be cell layers within organs (e.g. stem cells of
 193 the stomach wall) (see definitions for 'Target Region' and 'Target Tissue').

194 Active (bone) marrow

195 Active marrow is haematopoietically active and gets its red colour from the
 196 large numbers of erythrocytes (red blood cells) being produced. Active bone
 197 marrow serves as a target region for radiogenic risk of leukaemia.

198 Activity

199 The number of nuclear transformations of a radioactive material during an
 200 infinitesimal time interval, divided by its duration(s). The SI unit of activity is
 201 the becquerel (Bq): $1 \text{ Bq} = 1 \text{ s}^{-1}$

202 Becquerel (Bq)

203 Special name for the SI unit of activity. $1 \text{ Bq} = 1 \text{ s}^{-1}$, $1 \text{ MBq} = 10^6 \text{ Bq}$.

204 Biological half-life

205 The time required for a compartment of a biological system to eliminate (in
 206 the absence of additional input and radioactive decay) half of its radionuclide
 207 content.

208 Bone marrow [see also 'Active (bone) marrow'; 'Inactive (bone) marrow']

209 Bone marrow is a soft, highly cellular tissue that occupies the cylindrical
 210 cavities of long bones and the cavities defined by the bone trabeculae of the
 211 axial and appendicular skeleton. Total bone marrow consists of a sponge-like,
 212 reticular, connective tissue framework called stroma, myeloid (blood-cell-
 213 forming) tissue, fat cells (adipocytes), small accumulations of lymphatic tissue,
 214 and numerous blood vessels and sinusoids. There are two types of bone
 215 marrow: active (red) and inactive (yellow) where these adjectives refer to the
 216 marrow's potential for blood cell element production (haematopoiesis).

217 Committed effective dose, $E(\tau)$. See also ‘Effective Dose’.

218 In the Occupational Intakes of Radionuclides (OIR) report series, the
 219 integration time τ following the intake is taken to be 50 years. The committed
 220 effective dose $E(50)$ is calculated with the use of male and female committed
 221 equivalent doses to individual target organs or tissues, T according to the
 222 expression:

$$223 \quad E(50) = \sum_T w_T \cdot \left[\frac{H_T^M(50) + H_T^F(50)}{2} \right]$$

224 The SI unit for committed effective dose is the same as for absorbed dose, J
 225 kg^{-1} , and its special name is sievert (Sv).

226 Committed equivalent dose $H_T(50)$. See also ‘Equivalent Dose’.

227 In the OIR report series, the equivalent dose to an organ or tissue region is
 228 calculated using a 50-year commitment period. It is taken as the time integral
 229 of the equivalent dose rate in a target organ or tissue T of the Reference Adult
 230 Male or the Reference Adult Female. These in turn are predicted by reference
 231 biokinetic and dosimetric models following the intake of radioactive material
 232 into the body of the Reference Worker. The integration period is thus 50 years
 233 following the intake:

$$234 \quad H_T(50) = \int_0^{50} \dot{H}(r_T, t) dt$$

235 For both sexes, the equivalent dose rate $\dot{H}(r_T, t)$ in target region r_T at time t
 236 after an acute intake is expressed as:

$$237 \quad \dot{H}(r_T, t) = \sum_{r_S} A(r_S, t) \cdot S_w(r_T \leftarrow r_S)$$

239 where:

240
 241 $A(r_S, t)$ is the activity of the radionuclide in source region r_S at time t after
 242 intake, in Bq, as predicted by the reference biokinetic models for Reference
 243 Worker,
 244

245 $S_w(r_S \leftarrow r_T)$ is the radiation-weighted S coefficient; i.e. the equivalent dose to
 246 target region r_T per nuclear transformation in source region r_S , in $Sv (Bq s)^{-1}$,
 247 for the Reference Adult Male and Female.
 248

249 The SI unit for committed equivalent dose is the same as for absorbed dose, J
 250 kg^{-1} , and its special name is sievert (Sv).

251 Dose coefficient

252 For adult workers, a dose coefficient is defined as either the committed
 253 equivalent dose in organ or tissue T per intake, $H_T(50)$, or the committed
 254 effective dose per intake, $E(50)$, where 50 is the dose-commitment period in
 255 years over which the dose is calculated. Note that elsewhere the term ‘dose
 256 per intake coefficient’ is sometimes used for dose coefficient.

257 Effective dose, E

258 In accordance with the generic definition of effective dose in *Publication 103*,
 259 the effective dose is calculated as:

260
$$E = \sum_T w_T \left[\frac{H_T^M + H_T^F}{2} \right]$$

261 where H_T^M and H_T^F are the equivalent doses to the tissues or organs r_T of the
 262 Reference Adult Male and Female, respectively, and w_T is the tissue
 263 weighting factor for target tissue T, with $\sum_T w_T = 1$. The sum is performed

264 over all organs and tissues of the human body considered to be sensitive to the
 265 induction of stochastic effects. Since w_R and w_T are dimensionless, the SI unit
 266 for effective dose is the same as for absorbed dose, $J\ kg^{-1}$, and its special name
 267 is sievert (Sv).

268 Endosteum (or endosteal layer)

269 A 50- μm -thick layer covering the surfaces of the bone trabeculae in regions of
 270 trabecular spongiosa and those of the cortical surfaces of the medullary
 271 cavities within the shafts of all long bones. It is assumed to be the target
 272 region for radiogenic bone cancer. This target region replaces that previously
 273 introduced in *Publications 26* and *30* – the bone surfaces – which had been
 274 defined as a single cell layer, 10 μm in thickness, covering the surfaces of
 275 both the bone trabeculae and the Haversian canals of cortical bone.

276 Equivalent dose (H_T)

277 The equivalent dose to a tissue or organ is defined as:

278
$$H_T = \sum_R w_R D_{R,T}$$

279 where w_R is the radiation weighting factor for radiation type R, and $D_{R,T}$ is the
 280 organ absorbed dose from radiation type R in a tissue or organ r_T of the
 281 Reference Adult Male or Female. Since w_R is dimensionless, the SI unit for
 282 the equivalent dose is the same as for absorbed dose, $J\ kg^{-1}$, and its special
 283 name is sievert (Sv).

- 284 Gray (Gy)
285 The special name for the SI unit of absorbed dose: $1 \text{ Gy} = 1 \text{ J kg}^{-1}$.
- 286 Inactive (bone) marrow
287 In contrast to the active marrow, the inactive marrow is haematopoietically
288 inactive (i.e. does not directly support haematopoiesis). It gets its yellow
289 colour from fat cells (adipocytes) that occupy most of the space of the bone
290 marrow framework.
- 291 Marrow cellularity
292 The fraction of bone marrow volume in a given bone that is
293 haematopoietically active. Age- and bone-site-dependent reference values for
294 marrow cellularity are given in Table 41 of *Publication 70*. As a first
295 approximation, marrow cellularity may be thought of as 1 minus the fat
296 fraction of bone marrow.
- 297 Mean absorbed dose, $D_{R,T}$
298 The mean absorbed dose in a specified organ or tissue region r_T is given by

299 $D_T = 1/m_T \int D dm$, where m_T is the mass of the organ or tissue, and D is the
300 absorbed dose in the mass element dm . The SI unit of mean absorbed dose is
301 joule per kilogramme (J kg^{-1}), and its special name is gray (Gy).
- 302 Other tissues
303 A term used in biokinetic models to represent all other tissues that are not
304 already identified explicitly in the biokinetic model structure.
- 305 Other soft tissues
306 A term used in biokinetic models to represent all other tissues that are not
307 already identified explicitly in the biokinetic model structure, with the
308 exclusion of mineral bone in its cortical and trabecular forms.
- 309 Radiation weighting factor, w_R
310 A dimensionless factor by which the organ or tissue absorbed dose component
311 of a radiation type R is multiplied to reflect the relative biological
312 effectiveness of that radiation type. It is used to derive the organ equivalent
313 dose from the mean absorbed dose in an organ or tissue.
- 314 Red (bone) marrow
315 See ‘Active (bone) marrow’.
- 316 Reference Male and Reference Female
317 An idealised male or female with anatomical and physiological characteristics
318 defined by ICRP for the purpose of radiological protection.
- 319 Reference parameter value

- 320 The value of a parameter, factor or quantity that is regarded as valid for use in
321 dosimetric calculations and recommended by ICRP. These values are fixed
322 and are not subject to uncertainties.
- 323 Reference Person
- 324 An idealised person, for whom the equivalent doses to organs and tissues are
325 calculated by averaging the corresponding doses of the Reference Male and
326 Female. The equivalent doses of the Reference Person are used for the
327 calculation of the effective dose.
- 328 Reference phantom
- 329 The computational phantom of the human body (male or female voxel
330 phantom based on medical imaging data), defined in *Publication 110* with the
331 anatomical and physiological characteristics of the Reference Male and
332 Female defined in *Publication 89*.
- 333 Reference Worker
- 334 An adult Reference Person combined with the reference biokinetic and
335 dosimetric models and their parameter values, as defined in this report series
336 for the Reference Worker (systemic biokinetic models, the Human
337 Respiratory Tract Model, the Human Alimentary Tract Model, and dosimetric
338 models). The structure and parameter values of biokinetic models of the
339 Reference Worker are invariant on the sex, age, race and other individual-
340 specific characteristics, but based on reference male parameter values where
341 sex-specific models are available.
- 342 Sievert (Sv)
- 343 The special name for the SI unit (J kg^{-1}) of equivalent dose and effective dose.
- 344 Source region (r_s)
- 345 Region of the body containing the radionuclide. The region may be an organ,
346 a tissue, the contents of the alimentary tract or urinary bladder, or the surfaces
347 of tissues as in the skeleton and the respiratory tract.
- 348 Specific absorbed fraction (SAF), $\Phi(r_T \leftarrow r_S, E_{R,i})$
- 349 Fraction of radiation R of energy $E_{R,i}$ emitted within the source region r_S that
350 is absorbed per mass in the target region r_T .
- 351 Spongiosa
- 352 Term referring to the combined tissues of the bone trabeculae and marrow
353 tissues (both active and inactive) located beneath cortical bone cortices across
354 regions of the axial and appendicular skeleton. Spongiosa is one of three bone
355 regions defined in the *Publication 110* reference phantoms, the other two
356 being cortical bone and medullary marrow of the long bone shafts. As the
357 relative proportions of trabecular bone, active marrow, and inactive marrow
358 vary with skeletal site, the homogeneous elemental composition and mass

359 density of spongiosa are not constant but vary with skeletal site (see Annex B
360 of *Publication 110*).

361 S-coefficient (radiation-weighted) $S_w(r_T \leftarrow r_S)$

362 The equivalent dose to target region r_T per nuclear transformation of a given
363 radionuclide in source region r_S , Sv (Bq s)⁻¹, for the Reference Adult Male and
364 Reference Adult Female.

$$S_w(r_T \leftarrow r_S) = \sum_R w_R \sum_i E_{R,i} Y_{R,i} \Phi(r_T \leftarrow r_S, E_{R,i})$$

365 where

366 $E_{R,i}$ is the energy, in joules, of the i^{th} radiation of type R emitted in nuclear
367 transformations of the radionuclide;

368 $Y_{R,i}$ is the yield of the i^{th} radiation of type R per nuclear transformation,
369 (Bq s)⁻¹,

370 w_R is the radiation weighting factor for radiation type R (Table 1),

371 $\Phi(r_T \leftarrow r_S, E_{R,i})$ is the specific absorbed fraction (SAF), defined as the
372 fraction of energy $E_{R,i}$ of radiation type R emitted within the source region r_S
373 that is absorbed per mass in the target region r_T , kg⁻¹.

374 Note that no change in anatomical parameters with time (age) are considered
375 for adults; in this case, therefore, S_w is invariant with respect to time and its
376 value represents either the equivalent dose rate (Sv s⁻¹) per activity (Bq), or
377 the equivalent dose (Sv) per nuclear transformation (Bq-s) in the target region.

378 Target region (r_T)

379 Organ or tissue region of the body in which a radiation absorbed dose is
380 received.

381 Target tissue (T)

382 Organ or tissues in the body for which tissue weighting factors are assigned in
383 the effective dose (Table 2). In many cases, each target tissue T corresponds
384 to a single target region r_T . In the case of extrathoracic region, thoracic region,
385 colon, and lymphatic nodes, however, a fractional weighting of more than one
386 target region r_T defines the target tissue T (Table 3).

387 Tissue weighting factor, w_T . See also ‘Effective Dose’.

388 The factor by which the equivalent dose to an organ or tissue r_T is weighted to
389 represent the relative contribution of that organ or tissue to overall radiation
390 detriment from stochastic effects. It is defined as

391

$$\sum_T w_T = 1$$

392

393

394

1. INTRODUCTION

395 (1) The system of radiological protection recommended by the International
396 Commission on Radiological Protection (ICRP) is the basis for standards and
397 working practices throughout the world (ICRP, 1991, 2007; IAEA, 1996).
398 Fundamental to the application of ICRP recommendations are the protection
399 quantities defined by ICRP, equivalent dose and effective dose. While the definition
400 of these quantities remains unchanged in the most recent recommendations (ICRP,
401 2007), there have been important changes that affect the values calculated per
402 radiation exposure. Committee 2 of ICRP is responsible for the provision of these
403 reference dose coefficients for the assessment of internal radiation exposure,
404 calculated using reference biokinetic and dosimetric models, and reference data for
405 workers and members of the public. Following the 2007 Recommendations (ICRP,
406 2007), Committee 2 and its Task Groups engaged in a substantial programme of work
407 to provide new dose coefficients for various circumstances of radiation exposure.

408 (2) The underlying foundations of radionuclide dose coefficients for internal
409 exposures include several reference parameters and models. These include, among
410 others, (i) masses of organs and tissues in the Reference Adult Male and Female, (ii)
411 radionuclide decay information, (iii) biokinetic models for inhalation, ingestion, and
412 systemic biodistribution, and (iv) values of specific absorbed fractions (SAFs).
413 *Publications 89 and 107* (ICRP, 2002a, 2008) provide reference organ masses and
414 radionuclide decay data, respectively, as needed for calculations of internal dose
415 coefficients. *Publications 66 and 100* (ICRP, 1994a, 2006) provide models for
416 inhalation and ingestion of radionuclides, respectively. Presently, the ICRP Task
417 Group on Internal Dose Coefficients (IDC) is completing an extensive set of revisions
418 to its systemic biokinetic models within its Occupational Intakes of Radionuclides
419 (OIR) series of documents. The purpose of this report, prepared by the ICRP Task
420 Group on Computational Phantoms and Radiation Transport (CPRT), is to document
421 the development and provide data for SAFs for a wide range of internally emitted
422 radiations – photons, electrons, alpha particles, and in the case of radionuclides
423 undergoing spontaneous fission, neutrons – for all relevant combinations of source
424 and target tissues. The SAF is defined as the fraction of radiation energy emitted
425 within a source region that is absorbed per mass in a target region. These tissue
426 regions can be whole organs, organ sub-regions, individual cell layers, or tissue
427 interface surfaces. The values given in this report are for the ICRP Reference Adult
428 Male and Reference Adult Female, as defined in *Publication 103* (ICRP, 2007), and
429 are used within the OIR report series in the calculation of ICRP reference dose
430 coefficients for inhalation and ingestion. Further information is given in the OIR Part
431 1 (ICRP, 2015).

432

433

2. ICRP SCHEMA FOR INTERNAL DOSE ASSESSMENT

434

435 (3) The ICRP dosimetry schema is presented below as applied to assessment of
 436 organ equivalent dose and effective dose following intakes of radionuclides. The
 437 system involves numerical solution of reference biokinetic models, yielding the time-
 438 dependent number of nuclear transformations in various source tissues. These
 439 solutions are then coupled with reference data on nuclear decay information, target
 440 tissue masses, and fractions of emitted energy released from source tissue regions that
 441 are deposited in target tissue regions as defined in the *Publication 110* Reference
 442 Phantoms (ICRP, 2009). Presented below is the computational formalism of these
 443 dosimetry calculations consistent with the protection quantities defined in *Publication*
 444 *103* (ICRP, 2007).

445 (4) As defined in *Publication 103* (and this document's Glossary), the effective
 446 dose employs two forms of weighting factors. The first is the radiation weighting
 447 factor w_R used in the calculation of the organ equivalent dose (in Sv) given computed
 448 values of organ absorbed dose (in Gy). Values of w_R are shown in Table 1. The
 449 second is the tissue weighting factor w_T used in the calculation of the effective dose
 450 (in Sv) given computed values of sex-averaged organ equivalent doses. Values of w_T
 451 are shown in Table 2.

452

453 Table 1. ICRP radiation weighting factors

Radiation Type	Radiation Weighting Factor, w_R
Photons	1
Electrons and muons	1
Protons and charged pions	2
Alpha particles, fission fragments, heavy ions	20
Neutrons	Continuous function of neutron energy See Eqn. 4.3 of <i>Publication 103</i>

454

455

456 Table 2. ICRP tissue weighting factors.

Tissue	w_T	$\sum w_T$
Bone-marrow, breast, colon, lung, stomach, remainder tissues (13*)	0.12	0.72
Gonads	0.08	0.08
Urinary bladder, oesophagus, liver, thyroid	0.04	0.16
Bone surface, brain, salivary glands, skin	0.01	0.04

457

458 *Remainder Tissues: adrenals, extrathoracic (ET) regions of the respiratory tract, gall
 459 bladder, heart, kidneys, lymphatic nodes, muscle, oral mucosa, pancreas, prostate
 460 (male), small intestine, spleen, thymus, uterus/cervix (female).

461

462

2.1. Computational solutions to the ICRP reference biokinetic models

463 (5) The Human Respiratory Tract Model (HRTM) (ICRP, 1994a), the Human
 464 Alimentary Tract Model (HATM) (ICRP, 2006), and the systemic biokinetic models
 465 of this report describe the dynamic behaviour of radionuclides within the body. Given
 466 the routes of intake, the models predict the subsequent uptake to the systemic
 467 circulation, the distribution among tissues of the body, and the routes of elimination
 468 from the body. Superimposed on these dynamics are in situ radioactive decay and the
 469 ingrowth of radioactive progeny. Consequently, the uptake, distribution, and
 470 elimination of all decay products are predicted, in addition to those of the parent
 471 radionuclide.

472 (6) The compartment models of the respiratory and alimentary tract coupled with
 473 those of the systemic biokinetics define a system of first-order differential equations.
 474 The solution to the set of equations is the time-dependent distribution of the
 475 radionuclide and its radioactive progeny, if any, in mathematical compartments
 476 (pools) that are associated with anatomical regions in the body. Let $A_{i,j}(t)$ represent
 477 the activity of radionuclide i in compartment j at time t . The rate of change in the
 478 activity of member i of the decay chain, $i = 1, 2, \dots, N$ with $i = 1$ being the parent
 479 nuclide, in compartment j , can be written as:

480

$$\frac{dA_{i,j}(t)}{dt} = \sum_{\substack{k=1 \\ k \neq j}}^M A_{i,k} \lambda_{i,k,j} - A_{i,j} \left[\sum_{\substack{k=1 \\ k \neq j}}^M \lambda_{i,j,k} + \lambda_i^P \right] + \sum_{k=1}^{i-1} A_{k,j} \beta_{k,i} \lambda_i^P \quad (2.1)$$

481

482 where :

483 M is the number of compartments describing the kinetics;

484 $\lambda_{i,j,k}$ is the fractional transfer rate of chain member i from compartment j (donor
 485 compartment) to compartment k (receiving compartment) in the biokinetic
 486 model;

487 λ_i^P is the physical decay constant of chain member i ; and

488 $\beta_{k,i}$ is the fraction of the decays of chain member k forming member i .

489

490 (7) Given the initial conditions specified for the compartments, $A_{i,j}(0)$, Eqn. 2.1
 491 defines the dynamic behaviour of the radionuclide and its progeny within the human
 492 body. The first term on the right-hand side of Eqn. 2.1 represents the rate of flow of
 493 chain member i into compartment j from all donor compartments. The second term
 494 represents the rate of removal of member i from compartment j both by transfer to
 495 receiving compartments and by physical decay. The third term addresses the ingrowth
 496 of member i within compartment j due to the presence of its precursors k in the
 497 compartment. Note that the members of the decay chain are assumed to be of order
 498 such that the precursors of member i have indices less than i . An ordered listing of the
 499 chain members can be obtained using the DECDATA software distributed with
 500 *Publication 107* (ICRP, 2008).

501 (8) The system of $N \times M$ ordinary first-order differential equations must be solved
 502 using suitable numerical methods. The system is generally solved for the initial
 503 conditions that $A_{i,j}(0) = 0$ for all compartments with the exception of compartments
 504 of intake where nonzero initial conditions are only applied to the parent nuclide; i.e.
 505 $i = 1$. In the case of inhalation of radon and its progeny, nonzero initial conditions
 506 may be assigned to progeny within the compartments of the respiratory tract (i.e.
 507 inhalation of short-lived radon progeny in the inspired air).

508 (9) To calculate the numerical values of the dose coefficients, it is necessary to
 509 associate the biokinetic compartments of Eqn 2.1 with anatomical regions in the
 510 body; so-called source regions indexed by r_S . The source regions may or may not be a
 511 living tissue; e.g. the contents of the alimentary tract is not a living tissue, and may
 512 consist of more than one kinetic compartment. The number of nuclear transformations
 513 of chain member i occurring in source region r_S , $\tilde{A}_i(r_S)$ (Bq s), is given by:
 514

$$\tilde{A}_i(r_S, \tau) = \sum_j \int_0^\tau A_{i,j}(t) dt \quad (2.2)$$

515 where τ is the commitment period (taken to be 50 y for workers). The summation in
 516 Eqn 2.2 is over all kinetic compartments j associated with source region r_S and the
 517 quantity $A_{i,j}(t)$ is obtained by solving Eqn 2.1. The number of nuclear
 518 transformations per activity intake in the source region r_S , denoted as $\tilde{a}_i(r_S, \tau)$ (s), is
 519 given by:
 520

$$\tilde{a}_i(r_S, \tau) = \frac{\tilde{A}_i(r_S, \tau)}{\sum_j A_{1,j}(0)} \quad (2.3)$$

521 where the summation in the denominator is over the compartment contents at $t = 0$. In
 522 the case of inhalation of particulate and gaseous matter, the denominator includes the
 523 exhaled activity as only a fraction of the activity intake that is deposited in the
 524 compartments of the HRTM.
 525

526 2.2. Computation of ICRP reference dose coefficients for equivalent dose

528 (10) The committed equivalent dose coefficient in target region r_T of the Reference
 529 Adult Male, $h^M(r_T, \tau)$, and Reference Adult Female, $h^F(r_T, \tau)$, for integration time t
 530 is given by
 531

$$h^M(r_T, \tau) = \sum_i \sum_{r_S} \tilde{a}_i(r_S, \tau) S_w^M(r_T \leftarrow r_S)_i \quad (2.4)$$

$$h^F(r_T, \tau) = \sum_i \sum_{r_S} \tilde{a}_i(r_S, \tau) S_w^F(r_T \leftarrow r_S)_i \quad (2.5)$$

532 where the S coefficients, $S_w^M(r_T \leftarrow r_S)_i$ and $S_w^F(r_T \leftarrow r_S)_i$, are the radiation-weighted
 533 equivalent doses in target region r_T per nuclear transformation of chain member i in
 534 source region r_S [$\text{Sv} (\text{Bq s})^{-1}$] for the male and female worker, respectively. Note that
 535 the outer summation extends over the parent nuclide and its progeny.

536 (11) A number of tissues listed in Table 2 used to compute the effective dose are
 537 considered to be represented by a single target region r_T . In cases where more than
 538 one tissue region defines the target tissue, fractional weighting of the equivalent dose
 539 must be made. The committed equivalent dose coefficients for tissue T in the
 540 Reference Adult Male, $h_T^M(\tau)$, and Reference Adult Female, $h_T^F(\tau)$, are thus given as:
 541

$$h_T^M(\tau) = \sum_{r_T} f(r_T, T) h^M(r_T, \tau) \quad (2.6)$$

$$h_T^F(\tau) = \sum_{r_T} f(r_T, T) h^F(r_T, \tau) \quad (2.7)$$

542 where the target region fractional weights $f(r_T, T)$ are the proportions of the
 543 equivalent dose in tissue T associated with target region r_T . With the exception of the
 544 tissues addressed in Table 3, the tissues of Table 2 are represented by a single target
 545 region and thus for these tissues $f(r_T, T) = 1$. In Table 3, the values $f(r_T, T)$ for the
 546 ET and thoracic (TH or lung) regions are taken to be equivalent to their risk
 547 apportionment factors as assigned in the revised HRTM. For the colon, values of
 548 $f(r_T, T)$ are taken to be the fractional masses of the stem cell layers within the
 549 alimentary tract walls in *Publication 100* (ICRP, 2006). For the lymphatic nodes,
 550 values of $f(r_T, T)$ are taken to be the fractional masses of lymphatic nodes (not
 551 lymphatic tissues) within the extrathoracic, thoracic, and non-respiratory regions
 552 consistent with data given in *Publication 66* (ICRP, 1994).
 553
 554

Table 3. Target region fractional weights, $f(r_T, T)$

Tissue, T	r_T	$f(r_T, T)$
ET region	ET ₁ (anterior nose)	0.001
	ET ₂ (posterior nasal passages larynx and pharynx)	0.999
	Lung (Thoracic)	BB (bronchial)*
bb (bronchiolar)		1/3
AI (alveolar-interstitial)		1/3
Colon	Right colon	0.4
	Left colon	0.4
	Rectosigmoid	0.2
Lymphatic nodes	LN _{ET}	0.08
	LN _{TH}	0.08

Lymph (systemic)

0.84

*The basal and secretory cells are the two target regions weighted equally.

555
556
557

2.3. Computation of ICRP reference dose coefficients for effective dose

558 (12) As defined in *Publication 103* (ICRP, 2007), the committed effective dose
559 coefficient, $e(\tau)$, is then:
560

$$e(\tau) = \sum_T w_T \left[\frac{h_T^M(\tau) + h_T^F(\tau)}{2} \right] \quad (2.8)$$

561
562
563
564
565
566

where w_T is the tissue weighting factor for target tissue T and $h_T^M(\tau)$ and $h_T^F(\tau)$ are the corresponding committed equivalent dose coefficients for these same tissues in the Reference Adult Male and Reference Adult Female, respectively.

2.4. Implementation of specific absorbed fractions within the ICRP system

567 (13) The radiation-weighted S coefficient [Sv (Bq-s)^{-1}] for a radionuclide is
568 calculated as:
569

$$S_w(r_T \leftarrow r_S) = \sum_R w_R \sum_i E_{R,i} Y_{R,i} \Phi(r_T \leftarrow r_S, E_{R,i}) \quad (2.9)$$

570
571
572
573
574
575
576
577
578
579

where

$E_{R,i}$ is the energy of the i^{th} radiation of type R emitted in nuclear transformations of the radionuclide;

$Y_{R,i}$ is the yield of the i^{th} radiation of type R per nuclear transformation, $[(\text{Bq s})^{-1}]$;

w_R is the radiation weighting factor for radiation type R (Table 1); and

$\Phi(r_T \leftarrow r_S, E_{R,i})$ is the SAF, defined as the fraction of energy $E_{R,i}$ of radiation type R emitted within the source tissue r_S that is absorbed per mass in the target tissue r_T (kg^{-1}).

580
581
582
583
584
585
586
587

(14) The energies and yields of the emitted radiations, $E_{R,i}$ and $Y_{R,i}$, are taken from *Publication 107* (ICRP, 2008). For β emissions, the spectral data are used in the calculation of S_w rather than mean values; i.e. the inner summation in Eqn. 9 is replaced by the integral over the spectrum.

(15) SAF values given in this report are calculated as the ratio of the absorbed fraction (AF) and the target organ mass. Values of reference organ masses used in SAF calculations are listed in Annex A of this report and are assumed to be inclusive of the organ blood content. Values of the absorbed fraction are calculated by radiation

588 transport simulation using either voxelised or stylised (mathematically defined)
589 geometries as outlined further in Chapters 3 to 6.

590

591 **2.5. Derivation of specific absorbed fractions for distributed source organs**

592 (16) Systemic biokinetic models indicate radionuclide deposition from blood to
593 various identified source regions r_s , each with its own compartmental representation
594 in the biokinetic model. In many instances, the balance of radionuclide deposition
595 from blood will be assigned to “other tissues” of the body, which implies all other
596 soft tissues not previously identified as source organs. To address this source region,
597 which is generally unique to a given radionuclide biokinetic model, one must derive
598 the SAF for the relevant target tissues r_T . This SAF may be calculated using the so-
599 called additive approach as:

600

$$SAF(r_T \leftarrow Other) = \frac{1}{M_{Other}} \sum_{r_s} M_{r_s} SAF(r_T \leftarrow r_s) \quad (2.10)$$

601

602 where the summation is over source regions not explicitly included in the systemic
603 biokinetic model. Unless specifically noted in the biokinetic model, deposition to
604 other tissues is not assigned to mineral bone in either its cortical or trabecular form. A
605 summary of reference source tissue masses is given in Table A.2.

606

607

3. COMPUTATIONAL METHODS FOR WHOLE BODY ORGANS

608

3.1. The ICRP / ICRU reference computational phantoms

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649


650

(17) For the computations of organ absorbed doses, the adult male and female reference computational phantoms, representing the ICRP Reference Adult Male and Reference Adult Female (ICRP, 2007) were used in this report. These phantoms were adopted by the ICRP and ICRU as the phantoms for the computation of the ICRP reference dose coefficients and are extensively described in *Publication 110* (ICRP, 2009). The reference computational phantoms are digital three-dimensional (3D) representations of human anatomy and are based on human computed tomographic (CT) data. They are consistent with the information given in *Publication 89* (ICRP, 2002) on the reference anatomical parameters for both male and female adults. The reference computational phantoms (or models) were constructed by modifying the voxel models (Zankl and Wittmann, 2001; Zankl et al., 2005) of two individuals (Golem and Laura) whose body height and mass closely resembled the reference data. The organ masses of both phantoms were adjusted to the ICRP data on the Reference Male and Reference Female with high precision, without significantly altering their realistic anatomy. The phantoms contain all target regions relevant to the assessment of human exposure to ionising radiation for radiological protection purposes, i.e. all organs and tissues that contribute to the quantity effective dose (ICRP, 2007).

(18) Each phantom is represented in the form of a 3D array of cuboid voxels. Each voxel is a volume element, and the voxels are arranged in columns, in rows, and in slices. Each entry in the array identifies the organ or tissue to which the corresponding voxel belongs. The male reference computational phantom consists of approximately 1.95 million tissue voxels (excluding voxels representing the surrounding vacuum) each with a slice thickness (corresponding to the voxel height) of 8.0 mm and an in-plane resolution (i.e. voxel width and depth) of 2.137 mm, corresponding to a voxel volume of 36.54 mm³. The number of slices is 220, resulting in a body height of 1.76 m; the body mass is 73 kg. The female reference computational phantom consists of approximately 3.89 million tissue voxels, each with a slice thickness of 4.84 mm and an in-plane resolution of 1.775 mm, corresponding to a voxel volume of 15.25 mm³. The number of slices is 346, and the body height is 1.63 m; the body mass is 60 kg. The number of individually segmented structures is 136 in each phantom, and 53 different tissue compositions have been assigned to them. The various tissue compositions reflect both the elemental composition of the tissue parenchyma (ICRU, 1992a) and each organ's blood content (ICRP, 2002) (i.e. organ composition inclusive of blood). Fig. 1 shows frontal (coronal) views of the male (left) and female (right) computational phantom, respectively.

(19) Due to the limited resolution of the tomographic data on which these phantoms are based and the very small dimensions of some of the source and target regions, not all tissues could be explicitly represented. In the skeleton, for example, the target tissues of interest are the red bone marrow in the marrow cavities of spongiosa and the endosteal layer lining these cavities (presently assumed to be 50 µm in thickness). Due to their small dimensions, these two target tissues had to be

651 incorporated as homogeneous constituents of spongiosa within the reference
 652 phantoms. At lower energies of photon and neutrons, secondary charged-particle
 653 equilibrium is not fully established in these tissue regions over certain energy ranges.
 654 More refined techniques for accounting for these effects in skeletal dosimetry are
 655 discussed in Chapter 4.
 656



657
 658
 659
 660
 661
 662
 663
 664

Fig. 1. Images of the adult male (left) and adult female (right) computational phantoms. The following organs can be identified by different surface colours: breast, bones, colon, eyes, lungs, liver, pancreas, small intestine, stomach, teeth, thyroid and urinary bladder. Muscle and adipose tissue are semi-transparent. For illustration purposes, the voxelised surfaces have been smoothed.

665 (20) Similarly, the fine structure of some of the target regions in the human
 666 respiratory tract (HRT) and human alimentary tract (HAT) could not be described by
 667 the voxel geometry of the reference phantoms, and thus stylised models of the
 668 airways and of individual segments of the alimentary tract were employed for
 669 electrons and alpha particles in the respiratory and alimentary tracts. However, for
 670 photon SAFs and for electron cross-irradiation SAFs from and to source and target
 671 regions outside the HRT and HAT, the representations of these two organ systems as
 672 described in the reference computational phantoms were used.

673 (21) Small differences exist in the masses of the target tissues in the computational
674 phantom (given in Annex D of *Publication 110*) and the masses given in Table A.1 of
675 this report, as the latter includes the blood content of the target tissue. For cross-fire
676 geometries, Petoussi-Henss et al. (2007) demonstrate the principle given in MIRD
677 Pamphlet No. 5, Revised (Snyder et al., 1978) and MIRD Pamphlet No. 11 (Snyder et
678 al. 1975) that the SAF is independent of target mass. Consequently, all cross-fire
679 SAFs were calculated with the computational phantoms (Zankl et al., 2012),
680 according to the specifications of the source and target regions as given in Annex C
681 (source regions) and Annex D (target regions) of *Publication 110*. A summary of
682 source tissue masses is correspondingly given in Table A.2.

683 (22) Self-irradiation SAFs for all radiation types were calculated by taking the self-
684 irradiation AFs from the computational phantoms and dividing by the target mass
685 given in Table A.1 of this report. For self-irradiation geometries, Snyder (1970)
686 described the photon absorbed fraction varying in proportion to the cube root of the
687 target mass. This proportionality holds for photon energies and media where
688 Compton scattering is the dominant interaction. Since the differences in the
689 computational phantom organ mass and the reference target mass are small, simply
690 dividing the derived AF by the reference target mass results in only small absolute
691 differences in the SAF while allowing for an improved SAF at low photon energies.

692 (23) The blood source is an exception to the above cross-fire discussion, as the
693 blood content of the target contributed significantly to the energy deposition in the
694 target tissue. Thus, the target tissue SAF for the blood source for all radiations were
695 calculated by taking the cross-fire irradiation AFs and dividing by the target mass
696 given in Table A.1 of this report.

697 (24) This discussion does not apply to epithelial targets for the HATM and HRTM
698 as they are specified in terms of a tissue layer at depth.

699

700 **3.2. Radiation transport codes used for absorbed fraction calculations**

701 **3.2.1. Photon and electron transport calculations**

702 (25) For calculations of photon and electron absorbed fractions used in this report
703 for reporting corresponding SAFs, the electron-gamma-shower code system EGSnrc
704 Version v4-2-3-0 has been used (Kawrakow et al., 2009). This code is an extended
705 and improved version of EGS4 (Nelson et al., 1985), maintained by the National
706 Research Council of Canada (NRC). The transport of photons and electrons can be
707 simulated for particle kinetic energies from a few keV up to several hundred GeV,
708 although simulations performed in this study were made over the energy range of 10
709 keV to 10 MeV. Values below 10 keV were determined via extrapolation.


710 (26) For photon transport, bound Compton scattering and photo-electrons from K,
711 L, and M shells are considered for all energies. In both cases, resulting fluorescence
712 or Auger and Coster-Kronig electrons are followed. The input data for photon cross
713 sections have been updated by Seuntjens et al. (2002), who used the XCOM database
714 (Berger and Hubbell, 1987) to improve the cross sections for the photoelectric effect,
715 Rayleigh scattering, and pair production. Radiative Compton corrections in the one-
716 loop approximation based on the Brown and Feynman equation (1952) are applied.
717 However, the effect of reducing the cross section for large scattering angles is

718 partially cancelled by the inclusion of double-Compton events. For the pair-
719 production cross section, cross sections in EGS4 are employed following the
720 techniques of Øverbø et al. (1973). In this report, photon transport is terminated when
721 the photon energy falls below 2 keV.


722 (27) Electron transport calculations are performed by a Class II condensed history
723 technique (Berger, 1963), which transports secondary particles produced above a
724 certain chosen energy. Bremsstrahlung cross sections agree with those of the National
725 Institute of Standards and Technology (NIST) database (Seltzer and Berger, 1985,
726 1986), which in turn form the basis for the radiative stopping powers recommended
727 by the International Commission on Radiation Units and Measurements (ICRU,
728 1984). Electron impact ionisation is modelled using default cross sections (Kawrakow,
729 2002). For elastic scattering, spin effects are taken into account. Pair production is
730 simulated as in EGS4 (Nelson et al., 1985). Triplet-production processes are
731 neglected for all particles. In this report, the transport history of electrons is generally
732 terminated when their kinetic energy falls below 20 keV. Exceptions are noted for
733 electrons with an initial kinetic energy below 50 keV, whose histories are followed
734 down to 2 keV. A variance reduction technique called ‘bremsstrahlung splitting’ was
735 employed to decrease the relative statistical uncertainty in the dose conversion
736 coefficients of internal organs (Kawrakow et al., 2009).

737 (28) Representative plots of photon and electron SAFs are shown below in Figs. 2
738 to 6. For each source and target region combination, the photon SAFs are shown in
739 the upper panel of each figure, with the electron SAFs shown in the lower panel.

740




741
742
743




744
745
746
747
748
749
750

Fig. 2. SAFs to the adrenal glands within the reference adult male and reference adult female corresponding to uniformly distributed monoenergetic photon (A) and electron (B) sources in the kidneys.




751
752
753




754
755
756
757
758

Fig. 3. SAFs to the stomach walls within the reference adult male and reference adult female corresponding to uniformly distributed monoenergetic photon (A) and electron (B) sources in the liver.




759
760
761




762
763
764
765
766

Fig. 4. SAFs to the salivary glands within the reference adult male and reference adult female corresponding to uniformly distributed monoenergetic photon (A) and electron (B) sources in the thyroid.




767
768
769




770
771
772
773
774

Fig. 5. SAFs to the colon wall within the reference adult male and reference adult female corresponding to uniformly distributed monoenergetic photon (A) and electron (B) sources in the urinary bladder contents.



775
776
777



778
779
780
781
782

Fig. 6. SAFs to the prostate gland within the reference adult male and the uterus within the reference adult female corresponding to uniformly distributed monoenergetic photon (A) and electron (B) sources in the urinary bladder contents.

783 3.2.2. Neutron transport calculations

784 (29) For calculations of neutron absorbed fraction, the Los Alamos National
785 Laboratory Monte Carlo radiation transport code Monte Carlo N-Particle eXtended
786 (MCNPX) Version 2.6.0 has been used (Pelowitz 2008). MCNPX is capable of
787 tracking many particle types over broad energy ranges.

788 (30) The transport of neutrons, photons and electrons below 20 MeV is the same as
789 in the MCNP4C3 code, and is simulated using continue-energy nuclear, photoatomic,
790 and electron data libraries. Data libraries used for neutrons, photons, and electrons are
791 ENDF/B-VI, mcplib04, and el03, respectively. Thermal neutron scattering is strongly
792 dependent on the molecular binding energy of hydrogen. This effect is taken into
793 account by using $S(\alpha, \beta)$ data for hydrogen in water.

794 (31) In this report, values for neutron absorbed fraction were calculated for
795 neutrons from spontaneous fission having wide energy distribution expressed by the
796 Watt spectrum (ICRP, 2008). In the energy range considered in the present
797 calculation (<20 MeV), there are four main ways in which neutrons interact with
798 human tissue, namely, neutron capture, elastic scattering, inelastic scattering and
799 nuclear reactions. In the lower energy region, neutron capture is dominant although
800 the cross section usually decreases with the inverse square root of the neutron energy.
801 The 2.2 MeV photons, which are emitted by the capture of thermalised neutrons in
802 hydrogen via the ${}^1\text{H}(n, \gamma){}^2\text{D}$ reaction, play a significant role in the deposition of
803 energy in the human body. The ${}^{14}\text{N}(n, p){}^{14}\text{C}$ reaction, which produces protons of ~
804 600 keV, also contributes to the absorbed dose. At energies above ~1 keV, the energy
805 deposited by recoil protons from elastic scattering by hydrogen atoms becomes
806 significant. Inelastic scattering is reactions with energy thresholds in which the
807 neutron loses energy, exciting the nucleus to emit photons without the emission of
808 charged particles. At most, inelastic scattering contributes only to a small percent of
809 the total absorbed doses in body tissue. At energies above a few MeV, the production
810 of charged particles by nuclear reactions [(n, D), (n, T), (n, α), etc.] becomes an
811 increasingly significant mechanism for the deposition of energy.

812
813

3.3. Sampling algorithms for distributed organs and tissues

814 (32) For sampling points in different source regions, there are several cases to be
815 considered.

816
817

3.3.1. Sampling algorithm A

818 (33) The simplest situation is a single organ that is located at a specific position in
819 the body such as the brain, liver, pancreas, or spleen. The most straightforward
820 sampling method is then the following sampling algorithm.

821




Fig. 7. Schematic of sampling algorithm A.

822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838

3.3.2. Sampling algorithm B

(34) If a source region is distributed throughout the body such as muscle, sampling algorithm A may lead to a large proportion of rejected points. In this case, it may be better to use the following sampling algorithm.

(35) Let N be the number of voxels belonging to the region in question. These voxels are collected in a separate (N,3)-dimensional array NPOS. The value stored at NPOS(m,1) is the column, NPOS(m,2) is the row and NPOS(m,3) the slice where the mth voxel of the source region is located. To select a voxel, one multiplies N with a random number from the interval (0,1). The nearest integer number above this product is then used to identify a source voxel in the NPOS array. Then x, y and z coordinates are sampled independently inside the selected voxel. All sampled coordinate points can be used.




Fig. 8. Schematic of sampling algorithm B.

839
840
841

(36) In case the voxel number N of a source region is very large, there is a trade-off between wasted CPU time (in case of sampling algorithm A) and large storage requirement (sampling algorithm B). Selecting between these algorithms is at the discretion of the user.

842
843
844
845
846
847

3.3.3. Sampling algorithm C

848
849
850
851

(37) A further common situation is that of an organ pair where both organs are small, but they are relatively distant from each other, such as the adrenals. An efficient sampling algorithm may then be the following which is a combination of schemes A and B.

852
853
854
855
856
857
858
859

(38) Let N_l be the number of voxels belonging to the left one of an organ pair, N_r the number of voxels belonging to the right one, $N=N_l+N_r$ the sum of both, and $r_l=N_l/N$ the ratio of the voxel number of the left organ to that of both organs. If a sampled random number r is smaller than r_l , a source point is sampled according to algorithm A in the left organ, otherwise it is sampled in the right organ. This sampling algorithm can be extended to organ groups consisting of more than two parts.




Fig. 9. Schematic of sampling scheme C.

860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886

3.3.4. Sampling algorithm D

(39) The sampling algorithms mentioned above are for sources distributed homogeneously in the volume of an organ or organ group. There are, however, situations where inhomogeneous source distributions have to be considered. For example, consider a source uniformly distributed in trabecular bone which is not uniquely identified but is included within spongiosa. The same algorithm is equally applicable to marrow sources. There are mainly two recommended approaches.

(40) In this algorithm, the entirety of the segmented spongiosa voxels of all bones serves as volume in which one samples source points for particle emissions (using schemes A or B). However, since the relative amount of trabecular bone in the spongiosa varies between individual bones and bone groups, the source cannot be assumed as homogeneously distributed in volume. Therefore, the relative amount of trabecular bone in the segmented spongiosa volume of each specific bone or bone group is used as rejection criterion for accepting source points. Let $r_{t,b}$ be the relative amount of trabecular bone in the spongiosa of bone (group) b [respective data derived from Tables 3 and 4 in Zankl et al. (2005), see Table 4]. If a sampled random number r is smaller than $r_{t,b}$, the source point is accepted, otherwise rejected.

(41) This sampling algorithm is not optimal, since for each bone constituent and each spongiosa region, there is a nonzero probability of rejecting a sampled source point. Therefore, these data are normalised to the maximum value of each constituent among all spongiosa regions in Table 5. For the spongiosa region with the highest proportion of the respective bone constituent, all sampled source points are accepted; for all other spongiosa regions, the probability of rejection is reduced.

887 Table 4. Mass ratios of bone constituents (trabecular bone, red bone marrow, yellow
 888 bone marrow) in the spongiosa regions of the reference computational
 889 phantoms.
 890


Spongiosa region	Male			Female		
	Bone	RBM	YBM	Bone	RBM	YBM
Humeri, upper half	0.303	0.146	0.234	0.307	0.185	0.350
Humeri, lower half	0.195	0.000	0.600	0.230	0.000	0.652
Ulnae, radii (lower arm bones)	0.195	0.000	0.600	0.230	0.000	0.652
Hand bones	0.195	0.000	0.600	0.230	0.000	0.652
Clavicles	0.236	0.176	0.341	0.316	0.178	0.344
Skull (cranium)	0.242	0.197	0.306	0.385	0.164	0.255
Femora, upper half	0.202	0.166	0.419	0.094	0.268	0.589
Femora, lower half	0.195	0.000	0.600	0.230	0.000	0.652
Tibiae, fibulae, patellae	0.195	0.000	0.600	0.230	0.000	0.652
Foot bones	0.195	0.000	0.600	0.230	0.000	0.652
Mandible (facial skeleton)	0.330	0.127	0.197	0.311	0.208	0.322
Pelvis (os coxae)	0.189	0.301	0.311	0.186	0.354	0.365
Ribs	0.239	0.363	0.148	0.141	0.559	0.228
Scapulae	0.276	0.170	0.265	0.222	0.260	0.404
Cervical spine	0.062	0.620	0.253	0.213	0.482	0.197
Thoracic spine	0.101	0.563	0.229	0.127	0.574	0.234
Lumbar spine	0.161	0.476	0.194	0.267	0.424	0.173
Sacrum	0.029	0.668	0.272	0.071	0.634	0.259
Sternum	0.046	0.644	0.263	0.114	0.588	0.240

891 Table 5. Normalised mass ratios of bone constituents (trabecular bone, red bone
 892 marrow, yellow bone marrow) in the spongiosa regions. Compared to the
 893 data of Table 4, the entries of each column have been divided by the
 894 maximum entry in the respective column.
 895
 896

Spongiosa region	Male			Female		
	Bone	RBM	YBM	Bone	RBM	YBM
Humeri, upper half	0.916	0.218	0.391	0.799	0.292	0.538
Humeri, lower half	0.591	0.000	1.000	0.599	0.000	1.000
Ulnae, radii (lower arm bones)	0.591	0.000	1.000	0.599	0.000	1.000
Hand bones	0.591	0.000	1.000	0.599	0.000	1.000
Clavicles	0.713	0.264	0.568	0.822	0.281	0.528
Skull (cranium)	0.734	0.295	0.510	1.000	0.258	0.391
Femora, upper half	0.613	0.249	0.699	0.246	0.422	0.904
Femora, lower half	0.591	0.000	1.000	0.599	0.000	1.000
Tibiae, fibulae, patellae	0.591	0.000	1.000	0.599	0.000	1.000
Foot bones	0.591	0.000	1.000	0.599	0.000	1.000
Mandible (facial skeleton)	1.000	0.190	0.328	0.808	0.327	0.495

Pelvis (os coxae)	0.574	0.451	0.518	0.484	0.558	0.560
Ribs	0.723	0.544	0.247	0.366	0.882	0.350
Scapulae	0.835	0.255	0.441	0.578	0.410	0.620
Cervical spine	0.187	0.929	0.422	0.553	0.760	0.302
Thoracic spine	0.307	0.843	0.383	0.331	0.904	0.359
Lumbar spine	0.487	0.714	0.324	0.694	0.668	0.265
Sacrum	0.089	1.000	0.454	0.184	1.000	0.397
Sternum	0.138	0.965	0.438	0.295	0.928	0.368

897



898

899

900

901

Fig. 10. Schematic of sampling algorithm D.

902

3.3.5. Sampling algorithm E

903


904

905

906

907

(42) As with algorithm D, the whole spongiosa is taken as the volume from which source points can be sampled. In contrast to algorithm D, however, $r_{t,b}$, the relative amount of trabecular bone in the spongiosa of bone (group) b , is not used as criterion to accept or reject a source point, but each particle starting in the spongiosa volume is assigned this value as its initial "statistical weight".



908

909

910

Fig. 11. Schematic of sampling algorithm E.

911 (43) Sampling algorithm E is also recommended when the source is the whole
 912 body. Since homogeneous sources in the whole body should be considered to be
 913 distributed homogeneously by mass (not by volume), source points can be sampled
 914 uniformly in the whole body volume, and then the density of the organ/tissue where a
 915 source point is located can be assigned as statistical weight to the starting particle
 916 history.

917 (44) Another inhomogeneous source distribution arises when the source is the
 918 blood. The larger blood vessels have been segmented directly; here, the entire volume
 919 is blood source. However, the blood distribution inside the organs has been
 920 considered by including a respective proportion of blood in the tissue composition of
 921 each organ. Therefore, when a blood source has to be sampled, each organ contributes
 922 with the fraction of its mass that is due to blood. The blood fractions of the different
 923 tissues are given in Table 6. In this case, again either sampling algorithm D or
 924 sampling algorithm E is recommended.

925
 926 Table 6. Mass fraction of blood in the different body tissues.
 927

No.	Medium	Blood fraction	
		<i>Male</i>	<i>Female</i>
1	Teeth	0.000	0.000
2	Mineral bone	0.010	0.010
3	Humeri, upper half, spongiosa	0.054	0.060
4	Humeri, lower half, spongiosa	0.024	0.025
5	Lower arm bones, spongiosa	0.024	0.025
6	Hand bones, spongiosa	0.024	0.025
7	Clavicles, spongiosa	0.057	0.059
8	Cranium, spongiosa	0.061	0.060
9	Femora, upper half, spongiosa	0.053	0.015
10	Femora, lower half, spongiosa	0.024	0.025
11	Lower leg bones, spongiosa	0.024	0.025
12	Foot bones, spongiosa	0.024	0.025
13	Mandible, spongiosa	0.052	0.064
14	Pelvis, spongiosa	0.077	0.018
15	Ribs, spongiosa	0.090	0.013
16	Scapulae, spongiosa	0.058	0.068
17	Cervical spine, spongiosa	0.127	0.105
18	Thoracic spine, spongiosa	0.119	0.117
19	Lumbar spine, spongiosa	0.106	0.098
20	Sacrum, spongiosa	0.134	0.124
21	Sternum, spongiosa	0.131	0.118
22	Humeri and femora, upper halves, medullary cavity	0.015	0.014
23	Humeri and femora, lower halves, medullary cavity	0.015	0.014
24	Lower arm bones, medullary cavity	0.015	0.014
25	Lower leg bones, medullary cavity	0.015	0.014
26	Cartilage	0.015	0.014
27	Skin	0.051	0.054

28	Blood	1.000	1.000
29	Muscle tissue	0.027	0.025
30	Liver	0.311	0.293
31	Pancreas	0.240	0.205
32	Brain	0.046	0.038
33	Heart	0.027	0.025
34	Eyes	0.170	0.144
35	Kidneys	0.361	0.298
36	Stomach	0.295	0.234
37	Small intestine	0.327	0.260
38	Large intestine	0.333	0.251
39	Spleen	0.523	0.442
40	Thyroid	0.168	0.145
41	Urinary bladder	0.022	0.021
42	Testes / ovaries	0.064	0.075
43	Adrenals	0.240	0.189
44	Oesophagus	0.295	0.234
45	Gallbladder, pituitary gland, trachea, thymus, tonsils, ureters, ...	0.170	0.144
46	Prostate / uterus	0.170	0.144
47	Lymph	0.015	0.014
48	Breast (mammary gland)	0.170	0.144
49	Adipose tissue	0.019	0.018
50	Lung tissue (compressed lungs)	0.417	0.388
51	Gastro-intestinal tract - contents	0.000	0.000
52	Urine	0.000	0.000
53	Air	0.000	0.000

928

929 (45) The variables used in the above schematics that have not been explained in the
930 text are the following:

931

932 ID(i,j,k) the 3D voxel array of organ identification numbers

933 Voxdimx voxel dimension in x direction (column width)

934 Voxdimy voxel dimension in y direction (row depth)

935 Voxdimz voxel dimension in z direction (slice height)

936 xmin minimum x co-ordinate of the rectangular prism containing the organ in question

937 xmax maximum x co-ordinate of the rectangular prism containing the organ in question

938 ymin minimum y co-ordinate of the rectangular prism containing the organ in question

939 ymax maximum y co-ordinate of the rectangular prism containing the organ in question

940 xmin minimum x co-ordinate of the rectangular prism containing the organ in question

941 xmax maximum x co-ordinate of the rectangular prism containing the organ in question

942 random() random number with values in the interval (0,1)

943 wgt initial statistical weight of particle history (wgt = 1, if not specified otherwise)

944

945

4. COMPUTATIONAL METHODS FOR THE SKELETAL TISSUES

946 (46) For radiological protection purposes, the Commission defines two skeletal cell
947 populations of dosimetric interest relevant to stochastic biological effects: (i)
948 haematopoietic stem cells associated with the risk of radiogenic leukaemia, and (ii)
949 osteoprogenitor cells associated with the risk of radiogenic bone cancer. While data
950 now show that haematopoietic stem cells are found preferentially near the surfaces of
951 the bone trabeculae within skeletal spongiosa (Watchman et al., 2007; Bourke et al.,
952 2009), current modelling for radiological protection assumes these cells to be
953 uniformly distributed within the marrow cavities of haematopoietically active marrow.
954 For the osteoprogenitor cells, the Commission had previously defined their location
955 as a single cell layer within trabecular and cortical endosteum, each 10 μm in
956 thickness, and located along the surfaces of the bone trabeculae and Haversian canals,
957 respectively (ICRP, 1977). In *Publication 110* (ICRP, 2009), the surrogate target
958 tissue for the osteoprogenitor cells was redefined as being 50 μm in thickness along
959 the surfaces of the bone trabeculae in skeletal spongiosa, and along the inner surfaces
960 of the medullary cavities in the shafts of all long bones. As a result, cortical bone and
961 its cells within the Haversian canals are no longer considered to be a target tissue for
962 dose assessment. In this report, the revised 50 μm surrogate target tissue for the
963 osteoprogenitor cells is termed the ‘endosteum’ and is given the symbol TM_{50} (total
964 marrow within a 50-mm thickness of the bone surfaces). The term ‘bone surfaces’ is
965 no longer used to describe the target cell layer of relevance to radiogenic bone cancer.

966 (47) Neither of these skeletal target tissues at radiological risk can be geometrically
967 represented within the voxel structure of the ICRP reference phantoms. As presented
968 above, the skeleton in the male and female reference computational phantoms is
969 described by voxels defining either cortical bone, medullary marrow, or trabecular
970 spongiosa. The latter is a homogeneous mixture of its microscopic tissue constituents
971 – bone trabeculae, active marrow, and inactive marrow – and thus varies in both
972 elemental composition and mass density across different bones of the skeleton in each
973 reference phantom. Computational algorithms must therefore be applied to relate the
974 absorbed dose to spongiosa and medullary marrow to the absorbed dose to either
975 active marrow or endosteum. The elemental compositions of the constituent tissues of
976 trabecular spongiosa are given in Table 3.1 of *Publication 116* (ICRP, 2010). It is
977 further noted that the elemental composition of endosteum is equal to that of the
978 active marrow/inactive marrow mixture in a particular skeletal site as determined by
979 its reference marrow cellularity given in *Publication 70* (ICRP, 1995).

980

981

4.1. Models for electron transport

982 (48) Computations of SAFs for charged particles originating within the skeletal
983 tissues require detailed geometrical data on both (i) the bone macrostructure (i.e.
984 regions of spongiosa, cortical bone, and medullary marrow), and (ii) the bone
985 microstructure (i.e. regions of trabecular bone, active bone marrow, and inactive bone
986 marrow). While the former can be properly modelled with the structure of the
987 *Publication 110* reference computational phantoms, the latter requires additional
988 geometrical data for radiation transport within the trabecular spongiosa. In this report,

989 the microCT imaging data of Hough et al. (2011) were used for radiation transport
990 simulation in 38 cored samples of spongiosa imaged under microCT at an isotropic
991 resolution of 30 μm . The radiation transport code EGSnrc was used under Paired-
992 Image Radiation Transport to follow individual electrons simultaneously through
993 both the 3D geometry of ex-vivo CT images of the harvested bone sites and the 3D
994 geometry of the segmented microCT images of spongiosa (Hough et al., 2011).
995 Marrow voxels of the latter were randomly tagged as either active or inactive marrow
996 to achieve reference cellularities for each bone site. Radiation transport results were
997 reported as absorbed fractions for electrons over the energy range of 1 keV to 10
998 MeV. Source regions included bone marrow (both active and inactive), trabecular
999 bone (both volumes and surfaces), and cortical bone (both volumes and surfaces).
1000 The method utilised in Hough et al. (2011) (i) explicitly accounts for electron escape
1001 from spongiosa, (ii) explicit consideration of spongiosa cross-fire from cortical bone,
1002 and (iii) the revised 50- μm thickness of the endosteum target for bone cancer risk.
1003 SAF values reported in this report are ratios of the absorbed fractions calculated in
1004 Hough et al. (2011), and reference skeletal tissue masses for the ICRP Reference
1005 Adult Male and Reference Adult Female as defined in *Publication 110*.
1006
1007

4.2. Models for recoil proton transport following neutron interactions

1008 (49) Computations of absorbed fractions of energy for recoil protons originating in
1009 the skeleton have been performed using linear pathlength techniques. These
1010 techniques were first developed and described by the Spiers' group (Beddoe et al.,
1011 1976; Beddoe and Spiers, 1979; Spiers and Beddoe, 1977; Spiers et al., 1978a,b,
1012 1981; Whitwell and Spiers, 1976; Darley, 1972; Spiers, 1968; Whitwell, 1973),
1013 subsequently refined by Eckerman and Stabin (2000) and Bouchet et al. (1999), and
1014 most recently revisited by Jokisch et al. (2011a,b). This method was also the basis for
1015 recoil proton absorbed fractions used in neutron dose response functions as
1016 summarised in Annex E of *Publication 116* (ICRP, 2010). Distributions of linear
1017 pathlength segments across trabecular bone and marrow (inclusive of all soft tissue
1018 components) were obtained from the high resolution microCT images via digital
1019 measurements techniques described in Rajon and Bolch (2003) and Rajon et al.
1020 (2002) and published for the 40 year old male cadaver (Jokisch et al. 2011b).

1021 (50) These two pathlength distributions for a given skeletal site were then utilised
1022 in an algorithm (Jokisch et al. 2011a, b) that uses the continuous slowing down
1023 approximation (CSDA) range of the charged particle of interest to compute fractional
1024 energy deposition in the various skeletal tissues. This algorithm includes a basis for
1025 dividing the total marrow space (TMS) into active (AM) and inactive (IM)
1026 components based on typical sizes of skeletal adipose (Reverter et al. 1993). The
1027 endosteum (TM_{50}) portion of the TMS pathlength is determined via an algorithm
1028 developed by Jokisch et al. (2011a).

1029 (51) Range/energy data for protons utilising the CSDA were obtained from ICRU
1030 Report 49 (1993). Bragg-Kleeman scaling techniques described in Tsoufanidis
1031 (1983) were utilised to convert ICRU Report 49 Water to ICRU Report 46 (1992)
1032 Adult Red Marrow (used for AM) and Adult Yellow Marrow (used for IM). ICRU

1033 Report 49 Compact Bone was scaled to yield data for ICRU Report 46 Adult Cortical
1034 Bone (TBV).

1035 (52) When multiple trabecular cores comprise a single skeletal site, a source mass-
1036 weighted average absorbed fraction, of the constituent samples, x , was computed as
1037

$$\phi_{site} (r_T \leftarrow r_S) = \sum_x \frac{m_{x,S}}{m_{site,S}} \phi_x (r_T \leftarrow r_S) \quad (4.1)$$

1038 where $\frac{m_{x,S}}{m_{site,S}}$ is the fraction of total site source mass in sample x . Note that this
1039 method was also utilised to compute a skeletal averaged absorbed fraction using
1040 results from all skeletal sites.
1041

1042

1043

4.3. Models for alpha particle transport

1044 (53) Computations of SAFs of energy from alpha particles (2.0-12.0 MeV)
1045 originating in the skeleton were performed using three models: (1) the pathlength-
1046 based CSDA model described in paragraphs 49 and 50 but adapted for alpha
1047 particles; (2) a model performing CSDA range-based transport in voxelised images;
1048 and (3) a model using MCNPX (Waters, 2002; Pelowitz, 2008) alpha particle
1049 transport in voxelised images.

1050 (54) The first two models utilised identical CSDA range/energy data but differ
1051 slightly in their input geometry. While they both utilised data from the same 40 year
1052 male cadaver, the second model used the 3D voxelised image for the transport
1053 geometry whereas the first model utilised pathlength distributions obtained from
1054 those images. The second and third models used identical transport geometries (the
1055 voxel image) but differ in the radiation transport (CSDA compared MCNPX). As a
1056 result of the difference in geometry input, the pathlength model also differs slightly
1057 from the voxel models in the modeling of the endosteum target (TM₅₀), inactive
1058 marrow constituent (IM), and the algorithm for modeling radiation originating on the
1059 trabecular bone surface (TBS).

1060 (55) These differences form the basis for the recommended use of one model over
1061 another, or the averaging the results of two models for particular source/target
1062 combinations. For alpha particles originating in the active marrow irradiating the
1063 active marrow (AM←AM), the pathlength model was utilised since it is thought to
1064 have a more realistic modeling of the inactive marrow constituent. For a surface
1065 source irradiating the active marrow (AM←TBS), the CSDA voxel model was
1066 utilised since it has a marrow cellularity near the surface consistent with the
1067 cellularity of the entire marrow space. For the same reason, the CSDA voxel model
1068 was also utilised for alpha particles originating in the active marrow irradiating the
1069 endosteum (TM₅₀←AM). For the remaining endosteum (TM₅₀) target geometries, an
1070 average of the pathlength and voxel model results were used, as differences were
1071 observed but no basis for preference was determined. Finally, for the remaining active

1072 marrow (AM) target geometries, no significant differences were observed between
1073 the models.

1074

1075 **4.4. Response functions for photon and neutron dose to the skeletal tissues**

1076 (56) As noted above, the tissues of the skeleton at radiological risk, and hence
1077 assigned tissue weighting factors w_T , cannot be represented geometrically in the ICRP
1078 reference computational phantoms. The energy deposition in these tissues is
1079 influenced by their proximity to those of different densities and elemental
1080 compositions. This energy deposition can, however, be derived during the Monte
1081 Carlo calculations of photon transport through scaling the calculated photon fluence
1082 in different skeletal regions (spongiosa or medullary cavities) by functions
1083 representing the absorbed dose to the target tissue per photon (Eckerman, 1985;
1084 Eckerman et al., 2008; Johnson et al., 2011) or neutron fluence (Bahadori et al., 2011).
1085 These functions, referred to as response functions \mathcal{R} , are derived using models of the
1086 microscopic structure of bone geometry of different skeletal regions and the transport
1087 of the secondary ionising radiations through those geometries. For photons, these
1088 secondary radiations are electrons and positrons whose absorbed fractions within the
1089 skeletal tissues were developed in Hough et al. (2011). For neutrons, these secondary
1090 radiations are several, but most importantly recoil protons owing to their lower linear
1091 energy transfer (LET) and thus longer range within trabecular spongiosa (Jokisch et
1092 al., 2011a). In this work, all photon SAFs for target regions in the skeleton were
1093 derived using EGSnrc tabulations of energy-dependent photon fluence and photon
1094 skeletal dose response function presented in Annex D of *Publication 116* (ICRP,
1095 2010). Similarly, all neutron SAFs for target regions in the skeleton were derived
1096 using MCNPX tabulations of energy-dependent neutron fluence and neutron skeletal
1097 dose response functions presented in Annex E of *Publication 116* (ICRP, 2010).
1098

1099 **5. COMPUTATIONAL METHODS FOR THE RESPIRATORY TRACT**

1100 (57) Many of the electron and alpha particle absorbed fractions (AFs) tabulated in
 1101 Appendix H of *Publication 66* (ICRP, 1994) for the respiratory tract were adopted
 1102 directly in this document, with the following exceptions:

1103 (i) revisions to the respiratory tract particle transport model (ICRP, 2015) required
 1104 changes in dosimetric assumptions regarding the bronchial and bronchiolar
 1105 regions; and

1106 (ii) *Publication 66* electron SAFs were augmented with selected values from the
 1107 reference computational phantoms in cases where the absorbed fractions had
 1108 previously been assumed to be either unity or zero.

1109 (58) Revisions in the structure of the HRTM, in particular to the particle transport
 1110 model in the bronchial (BB) and bronchiolar (bb) regions, meant that the dosimetric
 1111 model for these sources had to be reconsidered. The original HRTM included particle
 1112 size-dependent slow clearance compartments, BB2 (bronchial) and bb2 (bronchiolar).
 1113 Material that cleared rapidly from these regions was represented by corresponding
 1114 compartments BB₁ and bb₁. Activity associated with the slow compartments was
 1115 assumed to be distributed within the ciliated sol layer adjacent to the airway walls and
 1116 activity in the fast compartments was taken to be dispersed throughout the mucous
 1117 gel overlaying the sol (ICRP, 1994). The size-dependent slow clearance
 1118 compartments were eliminated in the revised HRTM (ICRP, 2015) leaving a single
 1119 phase of clearance in both regions. Because of uncertainty in the location relative to
 1120 the target cells within the airway walls, of the activity being cleared in mucus, due to
 1121 factors including uncertainties in the values of the mean thicknesses of the two
 1122 mucous layers, activity in the revised BB and bb compartments is taken to be
 1123 uniformly distributed throughout both the gel and sol layers. The absorbed fractions
 1124 for the new single phase of clearance are weighted averages of those for the original
 1125 fast (gel) and slow (sol) compartments. The weights are the relative thicknesses of the
 1126 gel and sol layers, 5/11 and 6/11, respectively, for the bronchial region BB, and 2/6
 1127 and 4/6 for the bronchiolar region bb (ICRP, 1994). Thus, the revised electron and
 1128 alpha particle absorbed fractions for bronchial and bronchiolar surface sources are
 1129 given by:

1130

$$\phi(r_T \leftarrow BB) = \left(\frac{5}{11}\right)\phi(r_T \leftarrow BB_1) + \left(\frac{6}{11}\right)\phi(r_T \leftarrow BB_2) \quad (5.1)$$

$$\phi(r_T \leftarrow bb) = \left(\frac{2}{6}\right)\phi(r_T \leftarrow bb_1) + \left(\frac{4}{6}\right)\phi(r_T \leftarrow bb_2) \quad (5.2)$$

1131

1132 where r_T denotes the appropriate target tissue.

1133 (59) The *Publication 66* electron SAFs were supplemented with extra cross-fire
 1134 terms (when AF = 0) or improved self-dose values (when AF = 1) derived from
 1135 electron transport calculations in the male and female reference computational

1136 phantoms. For many organs in the reference phantoms, the SAFs computed for self-
1137 irradiation were approximately inversely proportional to mass with only minor or
1138 moderate deviations from mass scaling. This could be exploited in instances of self
1139 irradiation in the HRTM where target cells are located accurately in the phantom but
1140 with inadequate voxel resolution by correcting the SAFs with the reference mass.
1141 This applied to alveolar-interstitial and extrathoracic lymph node sources, replacing
1142 the original default assumption that $AF = 1$ for these cases and allowing for energy-
1143 dependent electron escape.

1144 (60) Electron cross-fire SAFs for many source and target combinations exhibited
1145 reciprocity over wide energy ranges, implying that the cross-fire SAFs were
1146 independent of source or target masses and did not require mass correction.
1147 Consequently, selected values could be used directly to fill any vacancies in the
1148 HRTM SAF matrix where cross-fire absorbed fractions had previously been assumed
1149 to be zero at all energies.

1150 (61) Alpha particle SAFs were not supplemented in this fashion. The electron and
1151 alpha particle absorbed fractions that were adopted from *Publication 66* were
1152 assumed to be gender-independent, but the SAFs derived from them used male or
1153 female target masses as appropriate. For consistency, the derived values were mapped
1154 onto the energy grid used for reference phantom radiation transport calculations.

1155
1156
1157

6. COMPUTATIONAL METHODS FOR THE ALIMENTARY TRACT

1158 (62) In *Publication 100*, the morphometric and dosimetric models of the
1159 alimentary tract are defined, including source regions of radionuclide deposition and
1160 target regions of radiosensitive stem cells. For electron sources in the alimentary tract,
1161 Annex F of *Publication 100* provided provisional values of SAFs based upon Monte
1162 Carlo radiation transport simulation in the geometric models of that report. Alpha
1163 particle transport was not considered in *Publication 100*, and thus values of SAF of
1164 alpha emissions presumed full energy deposition in the source region.

1165 (63) In the present report, new radiation transport simulations were performed for
1166 both electron and alpha particle sources using the geometric models described in
1167 Section 7.2 of *Publication 100*. The one exception was that of the small intestine wall.
1168 In *Publication 100*, a single tubular structure was adopted, while in the present report,
1169 a hexagonal array of tubular structures was adopted to allow for wall segment cross-
1170 fire. All radiation transport simulations were performed using MCNPX version 2.6
1171 (Pelowitz, 2008). Maximum particle energies considered were 10 MeV for electrons
1172 and 12 MeV for alpha particles.

1173

1174

REFERENCES

1175

1176 Bahadori, A.A., Johnson, P.B., Jokisch, D.W., Eckerman, K.F., Bolch, W.E., 2011.
1177 Response functions for computing absorbed dose to skeletal tissues from
1178 neutron irradiation. *Phys. Med. Biol.* 56, 6873–6897.

1179 Beddoe, A.H., Darley, P.J., Spiers, F.W., 1976. Measurements of trabecular bone
1180 structure in man. *Phys. Med. Biol.* 21, 589–607.

1181 Beddoe, A.H., Spiers, F.W., 1979. A comparative study of the dosimetry of bone-
1182 seeking radionuclides in man, rhesus monkey, beagle, and miniature pig.
1183 *Radiat. Res.* 80, 423–439.

1184 Berger, M.J., 1963. Monte Carlo calculation of the penetration and diffusion of fast
1185 charged particles. In: Alder, B., Fernbach, S., Rotenberg, M. (Eds.), *Methods*
1186 *in Computational Physics*. Academic Press, New York, pp. 135–215.

1187 Berger, M.J., Hubbell, J.H., 1987. XCOM: photon cross sections on a personal
1188 computer. NBSIR 87-3597. National Bureau of Standards (former name of
1189 NIST), Gaithersburg, MD.

1190 Bolch, W.E., Eckerman, K.F., Sgouros, G., Thomas, S.R., 2009. MIRDO Pamphlet No.
1191 21: A generalized schema for radiopharmaceutical dosimetry -
1192 Standardization of Nomenclature. *J. Nucl. Med.* 50, 477–484.

1193 Bouchet, L.G., Jokisch, D.W., Bolch, W.E., 1999. A three-dimensional transport
1194 model for determining absorbed fractions of energy for electrons within
1195 trabecular bone. *J. Nucl. Med.* 40, 1947–1966.

1196 Brown, L., Feynman, R., 1952. Radiative corrections to Compton scattering. *Phys.*
1197 *Rev.* 85, 231–244.

1198 Chadwick, M.B., Young, P.G., Chiba, S., et al., 1999. Cross section evaluations to
1199 150 MeV for accelerator-driven systems and implementation in MCNPX.
1200 *Nucl. Sci. Eng.* 131, 293–328.

1201 Cristy, M., 1980. Mathematical phantoms representing children of various ages for
1202 use in estimates of internal dose. Oak Ridge National Laboratory Report
1203 ORNL/NUREG/TM-367.

1204 Cristy, M., Eckerman, K.F., 1987. Specific absorbed fractions of energy at various
1205 ages for internal photon sources. Oak Ridge National Laboratory Report
1206 ORNL/NUREG/TM-8381, Vol. 1-7.

1207 Darley PJ 1972 Measurement of linear path length distributions in bone and bone
1208 marrow using a scanning technique Leeds, UK, University of Leeds.

1209 Eckerman, K.F., Westfal, R.J., Ryman, J.C., Cristy, M., 1994. Availability of nuclear
1210 decay data in electronic form, including beta spectra not previously published.
1211 *Health Phys.* 67, 338–345.

1212 Eckerman, K.F., Stabin, M.G., 2000. Electron absorbed fractions and dose conversion
1213 factors for marrow and bone by skeletal regions. *Health Phys.* 78, 199–214.

1214 Halbleib, J.A., Kensek, R.P., Valdez, G.D., et al., 1992. TS Version 3.0: the
1215 Integrated TIGER Series of Coupled Electron/Photon Monte Carlo Transport
1216 Codes SAND91-1634. Sandia National Laboratories, Albuquerque, New
1217 Mexico 87185 and Livermore, California 94550, US.

1218 Hough, M., Johnson, P., Rajon, D., Jokisch, D., Lee, C., Bolch, W.E., 2011. An
1219 image-based skeletal dosimetry model for the ICRP reference adult male -

- 1220 internal electron sources. *Phys. Med. Biol.* 56, 2309–2346.
- 1221 IAEA, 1996. Basic Safety Standards for Direct Methods for Measuring Radionuclides
1222 in the Human Body. Safety Series 114. International Atomic Energy Agency,
1223 Vienna, Austria.
- 1224 ICRU, 1992. Photon, electron, proton, and neutron interaction data for body tissues
1225 *ICRU Report 46 (Bethesda, MD: International Commission on Radiation*
1226 *Units and Measurements)*.
- 1227 ICRU, 1993. Stopping powers and ranges for protons and alpha particles *ICRU*
1228 *Report 49 (Bethesda, MD: International Commission on Radiation Units and*
1229 *Measurements)*.
- 1230 ICRP, 1975. Report on the Task Group on Reference Man. ICRP Publication 23.
1231 Pergamon Press, Oxford, UK.
- 1232 ICRP, 1977. Recommendations of the International Commission on Radiological
1233 Protection. ICRP Publication 26. *Ann. ICRP* 1(3).
- 1234 ICRP, 1979. Limits for intake of radionuclides by workers. ICRP Publication 30, Part
1235 1. *Ann. ICRP* 2(3/4).
- 1236 ICRP, 1980. Limits for intakes of radionuclides by workers. ICRP Publication 30,
1237 Part 2. *Ann. ICRP* 4(3/4).
- 1238 ICRP, 1981. Limits for intakes of radionuclides by workers. ICRP Publication 30,
1239 Part 3. *Ann. ICRP* 6 (2/3).
- 1240 ICRP, 1983. Radionuclide transformations: energy and intensity of emissions. ICRP
1241 Publication 38. *Ann. ICRP* 11-13.
- 1242 ICRP, 1986. The metabolism of plutonium and related elements. ICRP Publication 48,
1243 *Ann. ICRP* 16(2/3).
- 1244 ICRP, 1988a. Individual monitoring for intakes of radionuclides by workers: design
1245 and interpretation. ICRP Publication 54, *Ann. ICRP* 19(1-3).
- 1246 ICRP, 1988b. Limits for intakes of radionuclides by workers: An Addendum. ICRP
1247 Publication 30, Part 4. *Ann. ICRP* 19(4).
- 1248 ICRP, 1989. Age-dependent doses to members of the public from intake of
1249 radionuclides. ICRP Publication 56, Part 1. *Ann. ICRP* 20(2).
- 1250 ICRP, 1991. 1990 Recommendations of the ICRP. ICRP Publication 60. *Ann. ICRP*
1251 21(1-3).
- 1252 ICRP, 1993a. Protection against radon-222 at home and work. ICRP Publication 65.
1253 *Ann. ICRP* 23(2).
- 1254 ICRP, 1993b. Age-dependent doses to members of the public from intake of
1255 radionuclides: Part 2, Ingestion dose coefficients. ICRP Publication 67. *Ann.*
1256 *ICRP* 23(3/4).
- 1257 ICRP, 1994a. Human respiratory tract model for radiological protection. ICRP
1258 Publication 66. *Ann. ICRP* 24(1-3).
- 1259 ICRP, 1994b. Dose coefficients for intake of radionuclides by workers. ICRP
1260 Publication 68. *Ann. ICRP* 24(4).
- 1261 ICRP, 1995a. Basic anatomical and physiological data for use in radiological
1262 protection: The skeleton. ICRP Publication 70. *Ann. ICRP* 25(2).
- 1263 ICRP, 1995b. Age-dependent doses to members of the public from intake of
1264 radionuclides: Part 3, Ingestion dose coefficients. ICRP Publication 69. *Ann.*
1265 *ICRP* 25(1).

- 1266 ICRP, 1995c. Age-dependent doses to members of the public from intake of
1267 radionuclides: Part 4, Inhalation dose coefficients. ICRP Publication 71. Ann.
1268 ICRP 25(3/4).
- 1269 ICRP, 1996. Age-dependent doses to members of the public from intake of
1270 radionuclides: Part 5 Compilation of ingestion and inhalation dose coefficients.
1271 ICRP Publication 72. Ann. ICRP 26(1).
- 1272 ICRP, 1997a. General principles for the radiation protection of workers. ICRP
1273 Publication 75, Ann. ICRP 27(1).
- 1274 ICRP, 1997b. Individual monitoring for internal exposure of workers – Replacement
1275 of ICRP Publication 54. ICRP Publication 78. Ann. ICRP 27(3/4).
- 1276 ICRP, 2001. Dose to the embryo and fetus from intakes of radionuclides by the
1277 mother. ICRP Publication 88. Ann. ICRP 31(1-3).
- 1278 ICRP, 2002a. Basic anatomical and physiological data for use in radiological
1279 protection: reference values. ICRP Publication 89. Ann. ICRP 32(3-4).
- 1280 ICRP, 2002b. Guide for the practical applications of the ICRP Human Respiratory
1281 Tract Model. Supporting Guidance 3. Ann. ICRP 32(1/2).
- 1282 ICRP, 2004. Doses to the infant from radionuclides ingested in mothers' milk. ICRP
1283 Publication 95, Ann. ICRP 34(3/4).
- 1284 ICRP, 2005. Basis for dosimetric quantities used in radiological protection.
1285 Committee 2 Consultation Draft. www.icrp.org (May 2004).
- 1286 ICRP, 2006. Human alimentary tract model for radiological protection. ICRP
1287 Publication 100. Ann. ICRP 36(1/2).
- 1288 ICRP, 2007. The 2007 Recommendations of the International Commission on
1289 Radiological Protection. ICRP Publication 103. Ann. ICRP 37(2-4).
- 1290 ICRP, 2008. Nuclear decay data for dosimetric calculations. ICRP Publication 107.
1291 Ann. ICRP 38(3).
- 1292 ICRP, 2009. Adult reference computational phantoms. ICRP Publication 110. Ann.
1293 ICRP 39(2).
- 1294 ICRP, 2010. Conversion coefficients for radiological protection quantities for
1295 external radiation exposures. ICRP Publication 116. Ann. ICRP 40(1).
- 1296 ICRP, 2015. Occupational Intakes of Radionuclides: Part 1. ICRP Publication 130.
1297 Ann. ICRP 44(2).
- 1298 Johnson, P.B., Bahadori, A.A., Eckerman, K.F., Lee, C., Bolch, W.E., 2011.
1299 Response functions for computing absorbed dose to skeletal tissues from
1300 photon irradiation – an update. *Phys. Med. Biol.* 56, 2347–2366.
- 1301 Jokisch, D.W., Rajon, D.A., Bahadori, A.A., Bolch, W.E., 2011a. An image-based
1302 skeletal dosimetry model for the ICRP reference adult male – specific
1303 absorbed fractions for neutron-generated recoil protons. *Phys. Med. Biol.* 56,
1304 6857–6872.
- 1305 Jokisch, D.W., Rajon, D.A., Patton, P.W., Bolch, W.E., 2011b. Methods for the
1306 inclusion of shallow marrow and adipose tissue in pathlength-based skeletal
1307 dosimetry. *Phys. Med. Biol.* 56, 2699–2713.
- 1308 Kawrakow, I., 2002. Electron impact ionization cross sections for EGSnrc. *Med. Phys.*
1309 29, 1230.
- 1310 Kawrakow, I., Mainegra-Hing, E., Rogers, D.W.O., et al., 2009. The EGSnrc Code
1311 System: Monte Carlo Simulation of Electron and Photon Transport. PIRS
1312 Report 701. National Research Council of Canada, Ottawa.

- 1313 Kirk, B.L., 2010. Overview of Monte Carlo radiation transport codes. *Radiat. Meas.*
 1314 45, 1318–1322.
- 1315 Lee, C., Lamart, S., Moroz, B.E., 2013. Computational lymphatic node models in
 1316 pediatric and adult hybrid phantoms for radiation dosimetry. *Phys. Med. Biol.*
 1317 58, N59–N82.
- 1318 Nelson, W.R., Hirayama, H., Rogers, D.W.O., 1985. The EGS4 Code System. SLAC
 1319 Report 265. Stanford Linear Accelerator Center, Stanford, CA.
- 1320 Niita, K., Matsuda, N., Iwamoto, Y., et al., 2010. PHITS - Particle and Heavy Ion
 1321 Transport code System, Version 2.23. Japan Atomic Energy Agency, Tokai-
 1322 mura, Japan.
- 1323 Øverbø, I., Mork, K.J., Olsen, A., 1973. Pair production by photons: exact
 1324 calculations for unscreened atomic fields. *Phys. Rev. A* 8, 668–684.
- 1325 Pelowitz, D.B., 2008. MCNPX User's Manual, Version 2.6.0. LA-CP-07-1473, Los
 1326 Alamos National Laboratory Los Alamos, NM, USA.
- 1327 Petoussi-Hens N, WE Bolch, M Zankl, G Sgouros and B Wessels 2007 Patient-
 1328 specific scaling of reference S-values for cross-organ radionuclide S-values:
 1329 What is appropriate? *Radiat Prot Dosimetry* 127, 192-196.
- 1330 Rajon, D.A., Bolch, W.E., 2003. Marching cube algorithm: Review and trilinear
 1331 interpolation adaptation for image-based dosimetric models. *Comput. Med.*
 1332 *Image Graph.* 27, 411–435.
- 1333 Rajon, D.A., Jokisch, D.W., Patton, P.W., Shah, A.P., Watchman, C.J., Bolch, W.E.,
 1334 2002. Voxel effects within digital images of trabecular bone and their
 1335 consequences on chord-length distribution measurements. *Phys. Med. Biol.* 47,
 1336 1741–1759.
- 1337 Reverter, J., Feliu, E., Climent, C., Rozman, M., Berga, L., Rozman, C., 1993.
 1338 Sterological study of human bone marrow adipocytes: a comparison of four
 1339 methods for estimating size distributions. *Pathol. Res. Pract.* 189, 1215–1220.
- 1340 Seltzer, S.M., Berger, M.J., 1985. Bremsstrahlung spectra from electron interactions
 1341 with screened atomic nuclei and orbital electrons. *Nucl. Instrum. Methods*
 1342 *Phys. Res. Sect. B* 12, 95–134.
- 1343 Seltzer, S.M., Berger, M.J., 1986. Bremsstrahlung energy spectra from electrons with
 1344 kinetic energy from 1 keV to 10 GeV incident on screened nuclei and orbital
 1345 electrons of neutral atoms with $Z = 1-100$. *Atom. Data Nucl. Data Tables* 35,
 1346 345–418.
- 1347 Seuntjens, J.P., Kawrakow, I., Borg, J., et al., 2002. Calculated and measured air-
 1348 kerma response of ionization chambers in low and medium energy photon
 1349 beams. In: Seuntjens, J.P., Mobit, P. (Eds.), *Recent Developments in Accurate*
 1350 *Radiation Dosimetry, Proceedings of an International Workshop, Montreal,*
 1351 *July 14–18, 2002. Symposium Proceedings 13, Medical Physics Publishing,*
 1352 *Madison, USA. pp. 69–84.*
- 1353 Shah, A.P., Bolch, W.E., Rajon, D.A., Patton, P.W., Jokisch, D.W., 2005. A paired-
 1354 image radiation transport (PIRT) model for skeletal dosimetry. *J. Nucl. Med.*
 1355 46, 344–353.
- 1356 Snyder WS, MR Ford, GG Warner and EE Watson 1975 'S' absorbed dose per unit
 1357 cumulated activity for selected radionuclides and organs. *MIRD Pamphlet No.*
 1358 11, Revised. (New York, NY: Society of Nuclear Medicine)
- 1359 Snyder WS 1970 Estimation of absorbed fraction of energy from photon sources in

- 1360 body organs. In: Medical Radionuclides: Radiation dose and effects. Editors:
1361 RJ Cloutier, CL Edwards, WS Snyder. (US Atomic Energy Commission,
1362 Division of Technical Information (CONF-691212) pp. 33-49.
- 1363 Snyder WS, MR Ford and GG Warner 1978 Estimates of specific absorbed fractions
1364 for photon sources uniformly distributed in various organs of a heterogeneous
1365 phantom. MIRD Pamphlet No. 5, Revised. (New York, NY: Society of
1366 Nuclear Medicine)
- 1367 Spiers, F.W., 1968. Dosimetry at interfaces with special reference to base *Proc. Symp.*
1368 *on Microdosimetry (EAEC Publication)* pp 473–508.
- 1369 Spiers, F.W., Beddoe, A.H., 1977. 'Radial' scanning of trabecular bone: Consideration
1370 of the probability distributions of path lengths through cavities and trabeculae.
1371 *Phys. Med. Biol.* 22, 670–680.
- 1372 Spiers, F.W., Beddoe, A.H., Whitwell, J.R., 1978a. Mean skeletal dose factors for
1373 beta-particle emitters in human bone. Part i: Volume-seeking radionuclides.
1374 *Br. J. Radiol.* 51, 622–627.
- 1375 Spiers, F.W., Beddoe, A.H., Whitwell, J.R., 1981. Mean skeletal dose factors for
1376 beta-particle emitters in human bone. Part ii: Surface-seeking radionuclides.
1377 *Br. J. Radiol.* 54, 500–504.
- 1378 Spiers, F.W., Whitwell, J.R., Beddoe, A.H., 1978b. Calculated dose factors for the
1379 radiosensitive tissues in bone irradiated by surface-deposited radionuclides.
1380 *Phys. Med. Biol.* 23, 481–494.
- 1381 Tsoulfanidis, N., 1983. *Measurement and detection of radiation* Hemisphere
1382 Publishing Corp.
- 1383 Waters, L.S., 2002. MCNPX User's Manual, Version 2.3.0. Report LA-UR-02-2607.
1384 Los Alamos National Laboratory, Los Alamos, NM.
- 1385 Whitwell, J.R., 1973. Theoretical investigations of energy loss by ionizing particles in
1386 bone Leeds, UK, University of Leeds.
- 1387 Whitwell, J.R., Spiers, F.W., 1976. Calculated beta-ray dose factors for trabecular
1388 bone. *Phys. Med. Biol.* 21, 16–38.
- 1389 Young, P.G., Arthur, E.D., Chadwick, M.B., 1996. Comprehensive nuclear model
1390 calculations: theory and use of the GNASH code. In: Reffo, G.A. (Ed.), IAEA
1391 Workshop on Nuclear Reaction Data and Nuclear Reactors—Physics Design,
1392 and Safety, Trieste, 15 April–17 May, pp. 227–404.
- 1393 Zankl, M., Eckerman, K., Bolch, W.E., 2007. Voxel-based models representing the
1394 male and female ICRP reference adult – the skeleton. *Radiat. Prot. Dosim.*
1395 127, 174–186.
- 1396 Zankl, M., Fill, U., Petoussi-Hens, N., Regulla, D. 2002. Organ dose conversion
1397 coefficients for external photon irradiation of male and female voxel models.
1398 *Phys. Med. Biol.* 47, 2367–2385.
- 1399 Zankl, M., Petoussi-Hens, N., Fill, U., Regulla, D., 2003. The application of voxel
1400 phantoms to the internal dosimetry of radionuclides. *Radiat. Prot. Dosim.* 105,
1401 539–548.
- 1402 Zankl, M., Schlattl, H., Petoussi-Hens, N., Hoeschen, C., 2012. Electron specific
1403 absorbed fractions for the adult male and female ICRP/ICRU reference
1404 computational phantoms. *Phys. Med. Biol.* 57, 4501–4526.

1405 Ziegler, J.F., Biersack, J.P., Ziegler, M., et al., 2003. SRIM – the Stopping and Range
1406 of Ions in Matter. American Nuclear Society, La Grange Park, USA.
1407 Available at: www.srim.org (last accessed December 2011).
1408

Table A.1. Masses of Target Tissues in the Reference Adult Male and Female.

Target Tissue	Mass (kg)		Acronym	Reference
	Male	Female		
Brain	1.52	1.35	Brain	See note 1
Pituitary gland	7.12×10^{-4}	6.82×10^{-4}	P-gland	See note 1
Eye	1.57×10^{-2}	1.54×10^{-2}	Eye-lens	See note 2
Oral mucosa	0.0358	0.0225	O-mucosa	See note 2
Tongue	0.0745	0.0610	Tongue	See note 1
Tonsils	0.00350	0.00341	Tonsils	See note 1
Salivary glands	0.0853	0.0703	S-gland	See note 1
Oesophagus	9.5×10^{-5}	8.8×10^{-5}	Oesophagus	See note 3
Thymus	0.0293	0.0229	Thymus	See note 1
Breast	0.0254	0.500	Breast	See note 1
ET1 basal cells	2.0×10^{-5}	1.7×10^{-5}	ET1-bas	See note 4
ET2 basal cells	4.5×10^{-4}	3.9×10^{-4}	ET2-bas	See note 4
Extrathoracic lymph nodes	0.015	0.012	LN-ET	See note 4
Bronchi basal cells	4.3×10^{-4}	3.9×10^{-4}	Bronch-bas	See note 4
Bronchi secretory cells	8.6×10^{-4}	7.8×10^{-4}	Bronch-sec	See note 4
Bronchiolar secretory cells	1.9×10^{-3}	1.9×10^{-3}	Bchiol-sec	See note 4
Alveolar-interstitial	1.10	0.90	AI	See note 4
Thoracic lymph nodes	0.015	0.012	LN-Th	See note 4
Stomach	6.16×10^{-4}	6.16×10^{-4}	St-stem	See note 3
Small intestine	0.00371	0.00345	SI-stem	See note 3
Right colon	0.00135	0.00119	RC-stem	See note 3
Left colon	0.00126	0.0016	LC-stem	See note 3
Sigmoid colon	7.59×10^{-4}	6.99×10^{-4}	RS-stem	See note 3
Red (active) marrow	1.17	0.90	R-marrow	See note 1
Endosteal cells	0.544	0.407	Endost-BS	See note 5
Adrenals	0.0174	0.0155	Adrenals	See note 1
Thyroid	0.0234	0.0195	Thyroid	See note 1
Heart	0.339	0.256	Ht-wall	See note 1
Liver	2.36	1.81	Liver	See note 1
Gall bladder	0.0124	0.00948	GB-wall	See note 1
Kidneys	0.422	0.357	Kidneys	See note 1
Pancreas	0.174	0.145	Pancreas	See note 1
Spleen	0.228	0.187	Spleen	See note 1
Systemic lymph	0.148	0.118	LN-Sys	See note 6
Ureters	0.0187	0.0172	Ureters	See note 1
Uterus	-	0.0915	Uterus	See note 1
Prostate	0.0199	-	Prostate	See note 1
Urinary bladder	0.0511	0.0408	UB-wall	See note 1
Ovaries	-	0.0118	Ovaries	See note 1
Testes	0.0372	-	Testes	See note 1
Muscle	29.8	17.9	Muscle	See note 1
Adipose tissue	18.5	22.8	Adipose	See note 7
Skin	3.30	2.30	Skin	See note 1

Notes:

1. Based on Table 2.8 of *Publication 89* plus the blood content per *Publication 89*, p. 142.
2. Based on Table A.1 of *Publication 110* plus 0.010% of total blood mass.
3. Based on geometric model of *Publication 100* assuming a tissue density of 1.03 g/cm^3 .
4. Based on Table 5.3 of *Publication 89*.
5. Based on Table 3.2 of *Publication 116*.
6. Adopted mass of all lymph nodes as 178 and 143 g in male and female, respectively.

-
7. Sum of residual tissue masses in Table A.1 of *Publication 110* plus blood per *Publication 89*, p. 142.

1410

1411

Table A.2. Masses of Source Regions in the Reference Adult Male and Female.

Source Region	Mass (kg)		Acronym	Reference
	Male	Female		
Brain	1.45	1.30	Brain	<i>Publication 89, Table 2.8</i>
Pituitary gland	6×10^{-4}	6.0×10^{-4}	P-gland	<i>Publication 89, Table 2.8</i>
Eyes	0.015	0.015	Eyes	<i>Publication 89, Table 2.8</i>
Oral cavity	-	-	O-cavity	
Oral mucosa	0.0358	0.0225	O-mucosa	<i>Publication 110, Table A.1</i>
Salivary glands	0.085	0.070	S-glands	<i>Publication 89, Table 2.8</i>
Teeth surface	-	-	Teeth-S	
Teeth volume	0.050	0.040	Teeth-V	<i>Publication 89, Table 2.8</i>
Tongue	0.073	0.060	Tongue	<i>Publication 89, Table 2.8</i>
Tonsils	0.003	0.003	Tonsils	<i>Publication 89, Table 2.8</i>
Oesophagus - content	-	-	Oesophag-c	
Oesophagus	0.040	0.035	Oesophagus	<i>Publication 89, Table 2.8</i>
Breast	0.025	0.50	Breast	<i>Publication 89, Table 2.8</i>
Stomach contents	0.25	0.23	St-cont	<i>Publication 89, Table 2.8</i>
Stomach wall	0.15	0.14	St-wall	<i>Publication 89, Table 2.8</i>
Small intestine contents	0.35	0.28	SI-cont	<i>Publication 89, Table 2.8</i>
Small intestine villi			SI-villi	
Small intestine wall	0.65	0.60	SI-wall	<i>Publication 89, Table 2.8</i>
Right colon content	0.15	0.16	RC-cont	<i>Publication 89, Table 2.8</i>
Right colon wall	0.15	0.145	RC-wall	<i>Publication 89, Table 2.8</i>
Left colon content	0.075	0.080	LC-cont	<i>Publication 89, Table 2.8</i>
Left colon wall	0.15	0.145	LC-wall	<i>Publication 89, Table 2.8</i>
Sigmoid colon content	0.075	0.080	RS-cont	<i>Publication 89, Table 2.8</i>
Sigmoid colon wall	0.070	0.070	RS-wall	<i>Publication 89, Table 2.8</i>
ET1 surface	-	-	ET1-sur	
ET2 surface	-	-	ET2-sur	
ET2 bound region	2.47×10^{-3}	2.14×10^{-3}	ET2-bnd	See note 2
ET2 sequestered region	4.50×10^{-4}	3.89×10^{-4}	ET2-seq	See note 2
Extrathoracic lymph nodes	0.015	0.012	LN-ET	<i>Publication 66, Table 5</i>
Bronchial surface	-	-	Bronchi	
Bronchial bound region	1.73×10^{-3}	1.55×10^{-3}	Bronchi-b	See note 2
Bronchial sequestered region	2.92×10^{-4}	2.62×10^{-4}	Bronchi-q	See note 2
Bronchiolar surface	-	-	Bronchiole	
Bronchiolar bound region	4.89×10^{-3}	4.70×10^{-3}	Brchiole-b	See note 2
Bronchiolar sequestered region	1.25×10^{-3}	1.20×10^{-3}	Brchiole-q	See note 2
Alveolar-interstitial	1.10	0.90	AI	See note 2
Thoracic lymph nodes	0.015	0.012	LN-Th	<i>Publication 66, Table 5</i>
Cortical bone surface	-	-	C-bone-S	
Cortical bone	4.40	3.20	C-bone-V	<i>Publication 89, Table 2.8</i>
Trabecular bone surface	-	-	T-bone-S	
Trabecular bone	1.10	0.80	T-bone-V	<i>Publication 89, Table 2.8</i>
Cortical bone marrow	0.279	0.257	C-marrow	
Trabecular bone marrow	3.37	2.44	T-marrow	
Red (active) marrow	1.17	0.90	R-marrow	<i>Publication 89, Table 2.8</i>
Yellow (inactive) marrow	2.48	1.80	Y-marrow	<i>Publication 89, Table 2.8</i>
Blood	5.60	4.10	Blood	<i>Publication 89, Table 2.8</i>
Thyroid	0.020	0.017	Thyroid	<i>Publication 89, Table 2.8</i>
Thymus	0.025	0.020	Thymus	<i>Publication 89, Table 2.8</i>

Heart content	0.51	0.37	Ht-cont	<i>Publication 89, Table 2.8</i>
Heart	0.33	0.25	Ht-wall	<i>Publication 89, Table 2.8</i>
Adrenals	0.014	0.013	Adrenals	<i>Publication 89, Table 2.8</i>
Gall bladder content	0.058	0.048	GB-cont	<i>Publication 89, Table 2.8</i>
Gall bladder	0.010	0.008	GB-wall	<i>Publication 89, Table 2.8</i>
Kidneys	0.310	0.275	Kidneys	<i>Publication 89, Table 2.8</i>
Liver	1.80	1.40	Liver	<i>Publication 89, Table 2.8</i>
Systemic lymph	0.148	0.118	LN-Sys	See note 2
Pancreas	0.14	0.12	Pancreas	<i>Publication 89, Table 2.8</i>
Spleen	0.15	0.13	Spleen	<i>Publication 89, Table 2.8</i>
Testes	0.035	-	Testes	<i>Publication 89, Table 2.8</i>
Ovaries	-	0.011	Ovaries	<i>Publication 89, Table 2.8</i>
Ureters	0.016	0.015	Ureters	<i>Publication 89, Table 2.8</i>
Urinary bladder	0.050	0.040	UB-wall	<i>Publication 89, Table 2.8</i>
Urinary bladder content	0.20	0.20	UB-cont	
Uterus	-	0.080	Uterus	<i>Publication 89, Table 2.8</i>
Prostate	0.017	-	Prostate	<i>Publication 89, Table 2.8</i>
Muscle	29.0	17.5	Muscle	<i>Publication 89, Table 2.8</i>
Adipose	20.47	23.90	Adipose	See note 3
Cartilage	1.10	0.90	Cartilage	<i>Publication 89, Table 2.8</i>
Skin	3.30	2.30	Skin	<i>Publication 89, Table 2.8</i>

Notes:

1. Based on geometric model of *Publication 100* assuming a tissue density of 1.03 g/cm³.
2. Derived from information in *Publications 66* and *89*. Mass of all lymph nodes is 178 and 143 g in male and female, respectively.
3. Sum of residual tissue masses in *Publication 110*, Table A.1.

1414

ANNEX B

1415

DESCRIPTION OF ELECTRONIC FILES

1416

1417 The alpha, electron, photon, and neutron SAF files listed below have the same file
 1418 structure. The files are formatted as direct access files and are accompanied by two
 1419 index files which enable one to compute the SAF record of interest in the SAF files
 1420 given the acronyms of the target organ and source region. This brief note illustrates
 1421 how to use the files and how to derive the SAFs for Other Tissue as a source region.

1422

B.1. Alpha, Electron and Photon SAF Files

1423

1424

1425

The SAF files are:

RCP-AF_Alpha_2015-08-04.SAF
RCP-AF_Electron_2015-08-04.SAF
RCP-AF_Photon_2015-08-04.SAF
RCP-AM_Alpha_2015-08-04.SAF
RCP-AM_Electron_2015-08-04.SAF
RCP-AM_Photon_2015-08-04.SAF

1426

1427

where AF and AM denote adult female and adult male, respectively.

1428

1429

1430

1431

1432

1433

1434

1435

Each file has 5 header records thus the 6th record is the first SAF record and the last record is 3859 (47 target tissues x 82 source regions + 5 header records). The record length varies with radiation type. The record length of the electron and photon files is 315 and record length in the alpha SAF files is 270. The accompanying carriage return and line feed (CrLf) are not included in these lengths. The fields of the data record are

Target Tissue	10 characters	Acronym of target; e.g. UB-wall
Dummy	2 characters	Actually the characters "<-"
Source Region	10 characters	Source region acronym; e.g. UB-cont
SAF(1 to n)	E10.0	n SAF values (kg ⁻¹)
Ecut†	E10.0	Lowest energy of non-zero SAF
Icut	I3	Energy Index of Ecut
CrLf	2 characters	Carriage return and line feed

†Ecut format in alpha SAF files is F5.0

1436

1437

1438

1439

1440

The number of energies n addressed in the electron and photon files is 28. The alpha file addresses 24 energies and as noted above, in the alpha SAF file the Ecut parameter is of length 5 (F5.0).

1441

1442

1443

1444

The 4th record of each file lists the energies of the radiation corresponding to the SAF values. This record can be read assuming the above structure with the SAF fields containing the energy of the radiation corresponding to the SAF values. That is, for the 4th record in the electron and photon SAF files, the value of $E(i) = \text{SAF}(i)$, $i = 1$

1445 to 28. The unit of the energy values is MeV.

1446

1447 The Icut field contains the index of the lowest energy value for a non-zero SAF(T<-
1448 S). If all SAFs are zero then Icut is set to 0. If Icut has a value of j then nonzero SAF
1449 values are reported for energy values ranging from $E(j)$ to $E(n)$ where n is 28 in the
1450 electron/photon SAF files and 24 in the alpha SAF files. That is the number of non-
1451 zero SAF values is $n - j + 1$.

1452

1453 Some compilers require that the statement opening a file for random access specify
1454 the record length include the CrLf (add two to the above noted values) and others do
1455 not include the CrLf.

1456

1457

B.2. Neutron SAF Files

1458

The neutron SAF files are:

RCP-AF Neutron 2015-08-04.SAF
RCP-AM Neutron 2015-08-04.SAF

1459

1460

where AF and AM denote adult female and adult male, respectively.

1461

1462

1463

1464

1465

1466

1467

The neutron SAF file tabulates the SAF of the emitted neutron energy for each of the
47 target tissues and 82 source regions for those radionuclides in *Publication 107* for
which spontaneous fission is a decay mode. The 28 radionuclides are: U-238, Pu-236,
Pu-238, Pu-240, Pu-242, Pu-244, Cm-240, Cm-242, Cm-244, Cm-245, Cm-246, Cm-
248, Cm-250, Cf-246, Cf-248, Cf-249, Cf-250, Cf-252, Cf-254, Es-253, Es-254, Es-
254m, Es-255, Fm-252, Fm-254, Fm-255, Fm-256, and Fm-257.

1468

1469

1470

The fourth record in these files tabulates the spectral-average w_R for each
radionuclide. The data format of the neutron files is

Target Tissue	10 characters	Acronym of target; e.g. UB-wall
Dummy	2 characters	Actually the characters "<-"
Source Region	10 characters	Source region acronym; e.g. UB-cont
SAF(1 to 28)	E10.0	28 SAF values (kg^{-1})
CrLf	2 characters	Carriage return and line feed

1471

1472

1473

1474

1475

The record length in these files is 302. Some compilers require that the statement
opening a file for random access specify the record length include the CrLf (add two
to the above noted values) and others do not include the CrLf.

1476

1477

B.3. Target and Source Index Files

1478

1479

1480

1481

1482

The files TOrgans.NDX and SRegions.NDX list the target tissues and source regions,
respectively, in their order of appearance within the SAF files. The SAF files address
47 target tissues being irradiated by 82 source regions. The record number $irec$ of the
SAF for irradiation of the i^{th} target region by the j^{th} source region is

$$irec = 47(j - 1) + i + 5$$

1483
 1484 where 70 is the number of target tissues addressed in the files. For example, the
 1485 record addressing the irradiation of the 21th target region *Brain* by 10th source region
 1486 *St-cont* is

$$1487 \quad irec = 47(10 - 1) + 21 + 5 = 449$$

1488
 1489 which can be confirmed by opening an SAF file in an editor which indexes the file
 1490 records.

1491 **B.4. Deriving SAFs for Other Tissues**

1492
 1493 Frequently systemic biokinetic models will indicate deposition from *Blood* into a
 1494 compartment (or compartments) labeled as *Other* (or *Other_1*, *Other_2*, etc). To
 1495 address this source region, one must derive the *SAF* for the target tissues r_T being
 1496 irradiated by this source region; i.e. calculate $SAF(r_T \leftarrow Other)$. This may be calculated
 1497 as
 1498

$$1499 \quad SAF(r_T \leftarrow Other) = \frac{1}{M_{Other}} \sum_{r_S} M_{r_S} SAF(r_T \leftarrow r_S) \quad (B.1)$$

1500
 1501 where the summation extends over source regions not explicit noted in the systemic
 1502 biokinetic model. Source regions which are potential candidates are noted in
 1503 SRegions.NDX and marked with a gender-specific attribute *ID*. An *ID* value of 1
 1504 includes the source is a candidate for inclusion in *Other* (provided it is not present in
 1505 the biokinetic model). The *ID* column follows after the gender-specific mass of the
 1506 tissues. The mass of *Other* is the sum of the masses of the source regions comprising
 1507 *Other*. Eqn 1 is the so-called additive approach. Note that neither *C-bone-S* nor *T-*
 1508 *bone-S* (source regions representing activity on mineral bone surfaces) are part of
 1509 *Other* as no volume is associated with these regions.

1510 **B.5. Limiting SAF Values**

1511
 1512 The electron, photon, and alpha SAF files include limiting SAF values as the energy
 1513 of the radiation approaches zero; i.e. $\lim_{E \rightarrow 0} SAF(r_T \leftarrow r_S; E)$. The limiting value at E
 1514 = 0 and the nonzero values at 10 keV and above are used to derive values, by
 1515 interpolation, at 1 and 5 keV in the electron and photon files and at 1 and 1.5 MeV in
 1516 the alpha files. The additional low energy values are helpful in SAF interpolations
 1517 and extrapolations. The limiting SAF values are derived as:

1520
 1521 Solid organs:

$$\lim_{E \rightarrow 0} SAF(r_T \leftarrow r_S) = \begin{cases} \frac{1}{M_{r_T}}, & \text{if } r_S = r_T \\ 0, & \text{if } r_S \neq r_T \end{cases} \quad (\text{B.2})$$

1522

1523

HRTM: Limiting SAFs for a source in the bound region of the airways

1524

$$\lim_{E \rightarrow 0} SAF(ET2\ bas \leftarrow ET2\ bnd) = \frac{0.182}{M_{ET2\ bas}} \quad (\text{B.3a})$$

$$\lim_{E \rightarrow 0} SAF(Bronch\ bas \leftarrow Bronchi\ b) = \frac{0.250}{M_{Bronch\ bas}} \quad (\text{B.3b})$$

$$\lim_{E \rightarrow 0} SAF(Bronch\ sec \leftarrow Bronchi\ b) = \frac{0.500}{M_{Bronch\ sec}} \quad (\text{B.3c})$$

$$\lim_{E \rightarrow 0} SAF(Bchiol\ sec \leftarrow Brchiole\ b) = \frac{0.400}{M_{Bchiol\ sec}} \quad (\text{B.3d})$$

1525

1526

The numerical values in Eqns B.3 are the absorbed fractions at the lowest energy; e.g.

1527

10 keV in the case of photon and electrons, and 2 MeV for alpha particles. The

1528

limiting values for the sequestered source regions are zero.

1529

1530

Segments of the HATM: Limiting SAF for a source in the wall is

$$\lim_{E \rightarrow 0} SAF(X_{wall} \leftarrow Y_{wall}) = \begin{cases} \frac{1}{M_{Y_{wall}}}, & \text{if } X = Y \\ 0, & \text{if } X \neq Y \end{cases} \quad (\text{B.4})$$

1531

and for the source in the mucosa layer of the wall

$$\lim_{E \rightarrow 0} SAF(X_{wall} \leftarrow Y_{mucosa}) = \begin{cases} \frac{1}{M_{Y_{mucosa}}}, & \text{if } X = Y \\ 0, & \text{if } X \neq Y \end{cases} \quad (\text{B.5})$$

1532

1533

Blood:

$$\lim_{E \rightarrow 0} SAF(r_T \leftarrow Blood) = \frac{f_{r_T}}{M_{r_T}} \quad (\text{B.6})$$

1534

1535

where f_{r_T} is the mass fraction of the body's blood in the target r_T per *Publications 89*

1536

and *110*.

1537